Datasets:

FINDA-FIT

/

Fin_Corpus_News

like 1

NEWS_500

Conduent Business Services, LLC For the second consecutive year, Conduent is recognized among top companies focused on, making a difference in and selling to state and local government agencies FLORHAM PARK, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Conduent Incorporated (Nasdaq: CNDT), a global technology-led business process solutions company, has been named to the 2023 “GovTech 100” list of companies curated by Government Technology magazine. This is the second consecutive year that Conduent received the honor. The GovTech 100 list recognizes top companies “focused on, making a difference in and selling to” state and local government agencies across the United States. Begun in 2016 and updated annually, the list is created by a working group assembled by the magazine’s publisher that includes key market experts, government employees and investors. “We’re proud to again be named to the GovTech 100, which recognizes the critically important technology solutions and services we provide government agencies and their constituents every day,” said Mark King, President, Government Solutions at Conduent. “Our team remains focused on helping our clients automate and optimize the delivery of healthcare and social services to better serve residents, patients, families and individuals. We strive to improve the lives of those most in need by providing easier, more convenient access to payments, health information and healthcare.” Headquartered in New Jersey, Conduent provides government agencies with a range of solutions for healthcare, payments and eligibility services, as well as child support and constituent engagement. For example, Conduent supports approximately 41 million customers annually with various government health programs and processes more than 155 million Medicaid claims every year. Conduent’s offerings for agencies include Pharmacy Benefit Management solutions, the Conduent Medicaid Suite (CMdS) to help states move to a service-based MMIS system, and its Maven® Disease Surveillance and Outbreak Management Platform. Conduent recently introduced its BenePath® Suite, a comprehensive set of digital solutions designed to modernize the eligibility and enrollment process for social services and government aid programs. Also recently introduced are Conduent’s VeriSight solutions for identity validation and bank account owner verification, which are designed to help agencies combat fraud and strengthen benefit programs nationwide. Story continues In addition to these government services, Conduent Transportation provides mission-critical, smart mobility technology solutions that automate, streamline and optimize operations in road usage charging, transit, public safety and curbside management for U.S. and international transportation agencies. About Conduent Conduent delivers mission-critical services and solutions on behalf of businesses and governments – creating exceptional outcomes for its clients and the millions of people who count on them. Through our dedicated people, processes, and technologies, Conduent solutions and services enhance customer experience, increase efficiencies, reduce costs, and improve performance for most Fortune 100 companies and more than 500 government entities. Whether it’s touching three out of every four health insured lives and delivering 45% of SNAP payments in the U.S., or enabling 1.3 billion customer service interactions and empowering 10 million employees through HR services worldwide, Conduent services and solutions interact with millions of people every day and move our clients’ operations forward. Learn more at https://www.conduent.com. Media Contact: Neil Franz, Conduent, +1-240-687-0127, neil.franz@conduent.com Investor Relations Contact: Giles Goodburn, Conduent, +1-203-216-3546, ir@conduent.com Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives, and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent. Trademarks Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

NEWS_501

ZW Data Action Technologies Inc. BEIJING, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ZW Data Action Technologies, Inc. (Nasdaq: CNET) ("ZW Data" or the "Company"), an integrated online advertising, precision marketing, data analytics, and other value-added services company, today announced a strategic cooperation with Superwin Technology Pte. Ltd. (“Superwin”). Both parties intend to jointly establish a Web3.0 application service platform (“Platform”), through which the Company expects to provide basic computing power and blockchain services for Web3.0 application suppliers. The Company expects to bring commercial value to enterprise users and achieve efficiency in utilizing computing power resources, integrated management, and flexible scheduling, through the Platform. Superwin, headquartered in Singapore, operates data center, computing and mining facilities globally, and provides full compliant services to modern Blockchain Miners and other regional Cloud Service Providers in Singapore. Superwin collaborates with the regional leading and high graded data center operators, and also works with world’s leading data center solution suppliers, such as Inventec, Quanta and Huawei. It serves customers from Singapore, United States, Canada, Hong Kong (region), Taiwan (region), Germany, Japan, South Korea, Malaysia and other countries or regions.You can get more information in: http://www.superwintech.com/company. The two parties expect to establish the Platform with low-cost and cost-effective computing power and blockchain services for the Web3.0 applications suppliers. Superwin will provide the infrastructure of computing power, while the Company will provide the technology of establishing the Platform and blockchain services, and introduce Web3.0 applications in various scenarios into the Platform. Through the deployment of smart contracts, we believe that the Platform provides fast access services to partners with Web3.0 business needs, enabling them to use computing power resources more flexibly to complete data analysis and business computing tasks, and promote business processes and management activities. We anticipate that the Platform will be able to allocate computing power resources based on the needs of Web3.0 applications to maximize the use of computing power resources, and support Web3.0 application scenarios in various industries. “We are excited about the strategic cooperation with Superwin. The rapid development of Web3.0 industry is backed by the continuous development of computing power. Currently, the development of Web3.0 applications has reached the stage of commercialization. We plan to take advantage of the opportunities in the rapidly growing Web3.0 industry, and we believe in the great potential for improvement in the efficiency of computing power usage. We aim to reduce cost, increase efficiency, and support greater computing power demand with existing hardware scale for the Web3.0 application suppliers through the Platform. We believe that our approach to reducing the cost of computing power for Web3.0 applications will be meaningful for our clients and the development of the Web3.0 industry. Going forward, we will continue to explore business opportunities in the markets with high growth and great potential to increase our market presence and profitability,” commented Handong Cheng, Chairman and Chief Executive Officer of ZW Data. About ZW Data Action Technologies Inc. Established in 2003 and headquartered in Beijing, China, ZW Data Action Technologies Inc. (the “Company”) offers online advertising, precision marketing, data analytics and other value-added services for enterprise clients. Leveraging its fully integrated services platform, proprietary database, and cutting-edge algorithms, ZW Data Action Technologies delivers customized, result-driven business solutions for small and medium-sized enterprise clients in China. The Company also develops blockchain and artificial intelligence enabled web/mobile applications and software solutions for the general public, enterprise clients, and government agencies. More information about the Company can be found at: http://www.zdat.com/. Safe Harbor Statement This release contains certain "forward-looking statements" relating to the business of ZW Data Action Technologies Inc., which can be identified by the use of forward-looking terminology such as "believes," "expects," "anticipates," "estimates" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ZW Data Action Technologies Inc.’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting ZW Data Action Technologies Inc. will be those anticipated by ZW Data Action Technologies Inc. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ZW Data Action Technologies Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. For more information, please contact: Sherry Zheng Weitian Group LLC Email: shunyu.zheng@weitian-ir.com Phone: +1 718-213-7386

NEWS_502

CNH Industrial (CNHI) closed at $16.69 in the latest trading session, marking a -0.18% move from the prior day. This change lagged the S&P 500's daily loss of 0.08%. Meanwhile, the Dow lost 0.34%, and the Nasdaq, a tech-heavy index, added 11.55%. Coming into today, shares of the truck, tractor and bus maker had gained 4.57% in the past month. In that same time, the Auto-Tires-Trucks sector lost 20.56%, while the S&P 500 lost 1.03%. CNH Industrial will be looking to display strength as it nears its next earnings release. On that day, CNH Industrial is projected to report earnings of $0.35 per share, which would represent year-over-year growth of 40%. Our most recent consensus estimate is calling for quarterly revenue of $6.29 billion, down 30.62% from the year-ago period. Any recent changes to analyst estimates for CNH Industrial should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. CNH Industrial is currently a Zacks Rank #2 (Buy). In terms of valuation, CNH Industrial is currently trading at a Forward P/E ratio of 10.31. This valuation marks a premium compared to its industry's average Forward P/E of 6.75. The Automotive - Foreign industry is part of the Auto-Tires-Trucks sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 30% of all 250+ industries. Story continues The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CNH Industrial N.V. (CNHI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_503

CNH Industrial N.V. CASE_ IH_Planter New_Holland_Guardian_Sprayer_PLM New_Holland_ProBelt_CropCutter London, January 11, 2023 Case IH and New Holland, global agricultural brands of CNH Industrial, have won four 2023 ASABE AE50 awards from the American Society of Agricultural and Biological Engineers (ASABE). These prestigious awards honor the year’s 50 most innovative products and systems engineered for the food and agricultural industries. Case IH won its first award for the Early Riser® 2150S Front-Fold Split-Row Planter. It features a 50-inch split-row offset (front to back) design which maximizes residue flow and minimizes residue plugging – for more efficient and agronomic operation. The planter delivers accurate row unit ground following, seed placement and depth. All settings can be made directly from the cab allowing the farmer to easily apply the necessary adjustments to maximize productivity. New Steiger® Series Tractor Three-Point Hitch system is the brand’s second AE50-winning product. It is designed to maximize the power and lift capacity of wide-frame Steiger series tractors. The innovative system now has a 20,000-pound lift capacity and increased maximum lift height which will allow the tractor to tackle a wider variety of tasks on the farm. New Holland Agriculture was recognized for its 2023 Guardian™ Front Boom Sprayer with PLM Intelligence™ which features all-new electronic controls and offboard connectivity. Upgrades include liquid management system controls in the cab and fill station, and a full integration to the Precision Land Management (PLM) intelligence infrastructure offered by New Holland PLM connect systems and Raven Slingshot offboard interfaces. The PLM intelligence system benefits the customer by remotely providing diagnostics, service information and agronomic data straight to a phone, tablet, or home office – meaning they can make even more timely decisions to enhance overall profitability and productivity. Pro-Belt™ Series Variable Chamber Round Balers won New Holland’s second award. The balers are equipped with the ActiveDrop™ rotor drop floor which provides the durability required by baling contractors and high use farmers. The ActiveDrop rotor drop floor provides an alert to the operator when the load on the rotor is approaching maximum capacity. This allows the operator to adjust their baling speed to avoid rotor overloading and increases overall productivity. Story continues These awards recognize CNH Industrial’s ongoing development of customer-inspired, innovative products. CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions. Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world. For more information and the latest financial and sustainability reports visit: cnhindustrial.com For news from CNH Industrial and its Brands visit: media.cnhindustrial.com Media contacts: Rebecca Fabian Anna Angelini North America United Kingdom Tel. +1 312 515 2249 Tel. +44 (0)7725 826 007 mediarelations@cnhind.com Attachments

NEWS_504

CNH Industrial N.V. CNH_Industrial_Straw_Management_Solution CNH Industrial Straw Management Solution An innovative solution to an age-old problem. Watch our latest webisode on cnhindustrial.com London, January 5, 2023 “Agriculture has the word culture in it,” says Kavita Sah, Head of Corporate Social Responsibility at CNH Industrial India, in our latest installment in the Breaking New Ground webisode series. She goes on to explain how a huge cultural shift was required from local farmers who were used to burning their land to dispose of their waste straw. Working in partnership with the Ministry of Agriculture, CNH Industrial chose the village of Kallar Majri in the Punjab area of India to pilot its straw management technique in the year 2016. The results were impressive. The district eliminated all stubble burning by the end of the first year. Farmers quickly understood the benefits when they stopped this practice – reduced pollution, increased yield, and new income generation through the sale of their straw to power plants for renewable energy. The webisode contains insightful interviews with some of the farmers involved in the project. They explain the challenges that they had to overcome to adopt the straw management technique and share their hopes that others will follow their example. Following its initial success, the program has already been extended to an additional ten locations and a further eight locations are under evaluation. The straw management technique pioneered here is testimony to how CNH Industrial stands with the world’s farmers, making agriculture more sustainable and profitable. Watch here: bit.ly/BreakingNewGround_en CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions. Story continues Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world. For more information and the latest financial and sustainability reports visit: cnhindustrial.com For news from CNH Industrial and its Brands visit: media.cnhindustrial.com Media contacts: Rebecca Fabian Anna Angelini North America United Kingdom Tel. +1 312 515 2249 Tel. +44 (0)7725 826 007 mediarelations@cnhind.com Attachments

NEWS_505

NORTHAMPTON, MASS / ACCESSWIRE / January 9, 2023 / An innovative solution to an age-old problem. Watch our latest webisode on cnhindustrial.com "Agriculture has the word culture in it," says Kavita Sah, Head of Corporate Social Responsibility at CNH Industrial India, in our latest installment in the Breaking New Ground webisode series. She goes on to explain how a huge cultural shift was required from local farmers who were used to burning their land to dispose of their waste straw. Working in partnership with the Ministry of Agriculture, CNH Industrial chose the village of Kallar Majri in the Punjab area of India to pilot its straw management technique in the year 2016. The results were impressive. The district eliminated all stubble burning by the end of the first year. Farmers quickly understood the benefits when they stopped this practice - reduced pollution, increased yield, and new income generation through the sale of their straw to power plants for renewable energy. In October 2022, the company celebrated five years of the initiative. The webisode contains insightful interviews with some of the farmers involved in the project. They explain the challenges that they had to overcome to adopt the straw management technique and share their hopes that others will follow their example. Following its initial success, the program has already been extended to an additional ten locations and a further eight locations are under evaluation. The straw management technique pioneered here is testimony to how CNH Industrial stands with the world's farmers, making agriculture more sustainable and profitable. Watch here: bit.ly/BreakingNewGround_en View original content here CNH Industrial, Monday, January 9, 2023, Press release picture View additional multimedia and more ESG storytelling from CNH Industrial on 3blmedia.com. Contact Info: Spokesperson: CNH Industrial Website: https://www.3blmedia.com/profiles/cnh-industrial Email: info@3blmedia.com SOURCE: CNH Industrial View source version on accesswire.com: https://www.accesswire.com/734569/Breaking-New-Ground-CNH-Industrials-Straw-Management-Solution-in-India

NEWS_506

CNH Industrial NV has ended discussions with China's FAW Jiefang Co. over its on-highway business and will pursue existing plans to spin off the unit. The industrial-equipment manufacturer, whose largest shareholder is hol... The conventional wisdom is saying that after the high inflation and severe market losses of 2022, we’re in for a rough ride going forward. But there are always contrarian voices, giving alternate opinions and predictions –... CNH Industrial N.V. CNH Industrial NV designs, produces and sells agricultural equipment and commercial vehicles. It operates through the following business segments: Heavy construction equipment and Light construction equipment. The Heavy construction equipment segment includes general construction equipment such as large wheel loaders and excavators, and road building and site preparation equipment such as graders, compactors and dozers. Purchasers of heavy construction equipment include construction companies, municipalities, local governments, rental fleet owners, quarrying and mining companies, waste management companies and forestry-related concerns. The Light construction equipment is also know as compact and service equipment, and it includes skid-steer loaders, compact track loaders, tractor loaders, rough terrain forklifts, backhoe loaders, small wheel loaders and excavators. Purchasers of light construction equipment include contractors, residential builders, utilities, road construction companies, rental fleet owners, landscapers, logistics companies and farmers. The company was founded in 1866 and is headquartered in London, the United Kingdom.

NEWS_507

The Auto-Tires-Trucks group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has CNH Industrial (CNHI) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. CNH Industrial is a member of the Auto-Tires-Trucks sector. This group includes 123 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CNH Industrial is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for CNHI's full-year earnings has moved 7.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. According to our latest data, CNHI has moved about 0.3% on a year-to-date basis. In comparison, Auto-Tires-Trucks companies have returned an average of -55.8%. This means that CNH Industrial is outperforming the sector as a whole this year. Stellantis (STLA) is another Auto-Tires-Trucks stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 2.8%. The consensus estimate for Stellantis' current year EPS has increased 6% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy). Breaking things down more, CNH Industrial is a member of the Automotive - Foreign industry, which includes 28 individual companies and currently sits at #62 in the Zacks Industry Rank. On average, this group has lost an average of 41.5% so far this year, meaning that CNHI is performing better in terms of year-to-date returns. Stellantis is also part of the same industry. Story continues CNH Industrial and Stellantis could continue their solid performance, so investors interested in Auto-Tires-Trucks stocks should continue to pay close attention to these stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CNH Industrial N.V. (CNHI) : Free Stock Analysis Report Stellantis N.V. (STLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_508

NORTHAMPTON, MA / ACCESSWIRE / January 3, 2023 / At its Tech Day in Phoenix, Arizona, CNH Industrial revealed how investments in its tech culture will generate a consistent path forward for Ag tech development. They will also further position the Company as an employer of choice and customers' best answer to agriculture's biggest challenges today and tomorrow. In a panel hosted by Cherilyn Jolly-Nagel - a farmer from Saskatchewan, Canada - some of our engineering leaders explained how we are integrating and implementing this tech culture across our organization. They offered a deeper dive into our technology too. Those leaders were Mukesh Agarwal, VP of Precision Software and Cloud Applications; Dan Eslinger, VP of Precision and Vehicle Electronics; and John Preheim, VP of Raven Product Development. Click here to watch the full panel discussion now. More updates from CNH Industrial Tech Day are to follow on 3BL. #CNHIndustrial #BreakingNewGround #Tech #TechDay2022 CNH Industrial, Tuesday, January 3, 2023, Press release picture View additional multimedia and more ESG storytelling from CNH Industrial on 3blmedia.com. Contact Info: Spokesperson: CNH Industrial Website: www.cnhindustrial.com Email: info@3blmedia.com SOURCE: CNH Industrial View source version on accesswire.com: https://www.accesswire.com/733878/CNH-Industrial-Hosts-Precision-Tech-Panel-at-Tech-Day-2022

NEWS_509

New tour kicks off January 17, 2023 in St. Louis and travels all throughout the midwestern, western, southern and mid-Atlantic U.S. through March. RACINE, Wis., Jan. 12, 2023 /PRNewswire/ -- CASE Construction Equipment is launching the second leg of its Groundbreaker Roadshow celebrating the launch of the CASE Minotaur™ DL550 compact dozer loader — a first-of-its-kind machine and an all-new equipment category launched in 2022. The tour attracted crowds last Fall and put a huge exclamation point on one of the largest and most dynamic product launches of the year. The all-new machine was named to all major year-end awards lists, including Construction Equipment magazine's Top 100 New Products; Compact Equipment's Innovative Iron awards; and Heavy Equipment Guide's Top Introductions for 2022. The Groundbreaker Roadshow is coming to a CASE dealer near you! CASE is launching the second leg of its Groundbreaker Roadshow celebrating the CASE Minotaur™ DL550 compact dozer loader Attendees of The Groundbreaker Roadshow will experience the Minotaur firsthand while enjoying a day on the lot with chances for prizes and giveaways. The second leg of the Groundbreaker Roadshow kicks off on Tuesday, January 17 with Luby Equipment. For the full roadshow schedule, visit http://casece.com/Roadshow. More about The CASE Minotaur DL550 compact dozer loader Weighing in at more than 18,000 pounds and working with 114 horsepower, the new first-of-its-kind machine delivers true dozing and grading performance, as well as powerful site loading capabilities and compatibility with hundreds of attachments. A single platform has never delivered this level of versatility, power and precision — all culminating in an entirely new product category created by CASE: the compact dozer loader. The hallmark advancement of the CASE Minotaur DL550 is the chassis-integrated C-frame with six-way dozer blade. The C-frame hydraulically couples into both the chassis of the machine, as well as the attachment coupler. This design provides the stability and smooth operating plane of a small dozer while ensuring that all operating power is channeled through the whole body of the machine. This establishes greater performance and long-term reliability than the simple combination of a dozer blade attachment to a traditional compact track loader. Story continues It also comes standard with CASE Universal Machine Control, which makes the machine ready for any of the major three providers of machine control technology, which are sold separately. It's also available with an optional, industry-exclusive fully integrated ripper for tearing up tough terrain to simplify dozing and earthmoving operations. The C-frame is then detached to allow the operator to use it as a loader with a heavy-duty 1.25-cubic-yard bucket, or with hundreds of common loader attachments many equipment owners already have in their fleet. For more information on the all-new groundbreaking CASE Minotaur DL550 compact dozer loader, contact your local CASE dealer, and learn more at CaseCE.com/Minotaur. CASE Construction Equipment is a global full-line manufacturer of construction equipment that combines generations of manufacturing expertise with practical innovation. CASE is dedicated to improving productivity, simplifying operation and maintenance while achieving lower total cost of ownership for fleets around the world. The CASE dealer network sells and supports this world-class equipment, by offering customized aftermarket support packages, hundreds of attachments, genuine parts and fluids as well as industry-leading warranties and flexible financing. More than a manufacturer, CASE is committed to giving back by dedicating time, resources and equipment to building communities. This includes supporting disaster response, infrastructure investment, and non-profit organizations that provide housing and resources for those in need. CASE Construction Equipment is a brand of CNH Industrial N.V., a World leader in Capital Goods listed on the New York Stock Exchange (NYSE: CNHI) and on the Mercato Telematico Azionario of the Borsa Italiana (MI: CNHI). More information about CNH Industrial can be found online at http://www.cnhindustrial.com/. The CASE Minotaur DL550 Compact Dozer Loader CASE Construction Equipment (PRNewsFoto/CASE Construction Equipment) (PRNewsfoto/CASE Construction Equipment) Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-case-groundbreaker-roadshow-takes-a-second-tour-through-the-us-to-celebrate-the-launch-of-the-minotaur-dl550-compact-dozer-loader-301720506.html SOURCE CASE Construction Equipment

NEWS_510

NORTHAMPTON, MA / ACCESSWIRE / January 5, 2023 / CNH Industrial CNH Industrial announced during its Tech Day in Phoenix, Arizona, USA, that it has opened a new technical center in the Detroit Metro area of Michigan, USA. Designed to support our growing innovation in electrification, the center will enhance CNH Industrial's technology capabilities. This is facilitated by its proximity to a nationwide hub for electrification OEMs and suppliers. "This new location underlines our commitment to growing our electric vehicle and subsystem profile, and marks yet another milestone after successfully expanding our in-house team," said Marc Kermisch, Chief Digital and Information Officer and ad interim Chief Technology & Quality Officer, CNH Industrial. "Under one roof our team can now leverage cross-functional and cross-sector expertise at both component and machine level. The result sees us becoming more customer-focused and building mission-fit electrified drivetrains and high voltage systems." Expanding our electric footprint This new site will complement and partner with the Company's existing electrification site in San Matteo, Modena, Italy. Together, they will further our leading position in alternative propulsion - built on over 15 years of R&D experience and commercially available products. The Detroit Tech Center positions CNH Industrial alongside external thought leaders and gamechangers to accelerate innovation and deliver new use cases and applications in Agriculture and Construction. "As an employer we are investing in talented and motivated people who augment our in-house electrification capabilities," said Kevin Barr, Chief Human Resource Officer, CNH Industrial. "This new hub means we can tap into a unique talent pool who will change the face of agriculture in the years to come." More updates from CNH Industrial Tech Day are to follow on 3BL. #CNHIndustrial #BreakingNewGround #Tech #TechDay2022 View original content here. Story continues CNH Industrial, Thursday, January 5, 2023, Press release picture View additional multimedia and more ESG storytelling from CNH Industrial on 3blmedia.com. Contact Info: Spokesperson: CNH Industrial Website: https://www.3blmedia.com/profiles/cnh-industrial Email: info@3blmedia.com SOURCE: CNH Industrial View source version on accesswire.com: https://www.accesswire.com/734278/CNH-Industrials-New-Electrification-Center-in-Detroit-USA

NEWS_511

NORTHAMPTON, MA / ACCESSWIRE / January 12, 2023 / CNH Industrial debuted its latest automation and autonomy solutions at its Tech Day in Phoenix, Arizona. New Driverless Tillage and Driver Assist Harvest solutions from Raven, and Baler Automation from Case IH and New Holland, deliver automation and autonomous equipment enhancements. They all help solve farming's biggest challenges: to increase productivity and to do more with less resources, more sustainably. These latest technology developments form part of our Ag Tech roadmap. "The agriculture industry is faced with the challenges of time, costs, constrained operational windows, and a dwindling labor force. Autonomy will become an integral part of farmers' operations everywhere," said Derek Neilson, President, Agriculture. "We believe that Autonomy and Automation technologies are fundamental to the future of farming. They cover all farmer segments and drive real world benefits." Driver Assist Harvest Solution This new automation technology for the tractor platform leverages our Case IH brand's harvest technology with Raven Autonomy integration. It provides a coordinated control feature that allows for the Driver Assist Harvest Solution to chart the path and speed of the tractor pulling the grain cart alongside a combine harvester during an ‘unload on the go' operation. The Driver Assist Harvest Solutions keeps the tractor perfectly in sync with the combine harvester when unloading grain - giving the combine operator seamless control over the unloading process. This makes the full operation more efficient, with less grain spillage in the process. Our new technology helps remedy the lack of skilled labor by simplifying the task. It also provides a better user experience with less operator fatigue. This solution will be made commercially available for both Case IH and New Holland brands. Driverless Tillage Solution The driverless tillage solution features an advanced Perception System and Remote Command & Control experience from Raven Autonomy, which functions with no operator in the cab. The machine can be operated remotely from a mobile tablet device. The operator can plan and execute precise, automated missions with consistent agronomic results monitored from anywhere. Story continues This development combines the Case IH tractor and tillage platform with Raven autonomy to deliver this autonomous tillage solution. The Raven Autonomy technology platform provides a flexible, scalable tech stack to the iron. This solution also leverages existing Case IH tillage automation for ultimate agronomic and machine control of the implement. The result is increased productivity with consistent agronomic performance and richer data insights. Case IH and New Holland's significant automation developments are continuing to accelerate with the ongoing integration of Raven. Baling Automation Industry-first Baler Automation was also unveiled on New Holland large square balers, featuring new technology that uses a LiDAR sensor to that scan the windrow in front of the tractor for density, volume and direction. The tractor and baler then use this input to automatically control steering, forward speed and baler settings to ensure the baler follows the windrow precisely for accurate crop feeding. The result? Optimized bale shape, increased productivity, operator comfort and reduced fuel consumption. Case IH will also offer the baling automation feature. Automation and Autonomy technology milestones in the field We have a proven track record of existing world class technologies on our agriculture equipment. Earlier this year at the Farm Progress Show in Boone, Iowa, USA, Case IH and Raven introduced the agriculture industry's first autonomous spreader, the Case IH Trident™ 5550 applicator with Raven Autonomy™ (Driverless Spreading Solution). Meanwhile both New Holland and Case IH combines offer award-winning, best-in-class combine automation, and both Case IH Patriot and New Holland Guardian sprayers that come equipped with application control automation. "We're on the road to full autonomy. We focus on delivering an autonomous tech stack that scales across all production cycles for the cash crop segment: crop preparation, planting/seeding, crop care, harvest, hay, and forage. Focusing on automation and autonomy is not taking farmers out of farming it's making their machines more productive with functional automation," said Parag Garg, CNH Industrial Chief Digital Product Officer. "Our focus is to make the Precision Technology on our equipment so smart, that the customer can focus on the farm and let CNH Industrial take care of rest." At CNH Industrial we are Breaking New Ground to help solve farmers' real-world problems by unlocking additional value through automated and autonomous solutions. See other Flexible Media Releases from CNH Industrial for more on Tech Day. #CNHIndustrial #BreakingNewGround #Tech #TechDay2022 View original content here. CNH Industrial, Thursday, January 12, 2023, Press release picture Case IH Trident 5550 with Raven Autonomy showing support View additional multimedia and more ESG storytelling from CNH Industrial on 3blmedia.com. Contact Info: Spokesperson: CNH Industrial Website: https://www.3blmedia.com/profiles/cnh-industrial Email: info@3blmedia.com SOURCE: CNH Industrial View source version on accesswire.com: https://www.accesswire.com/735131/CNH-Industrial-Adds-New-Automation-and-Autonomy-Solutions-to-Ag-Tech-Portfolio

NEWS_512

The conventional wisdom is saying that after the high inflation and severe market losses of 2022, we’re in for a rough ride going forward. But there are always contrarian voices, giving alternate opinions and predictions – and that’s what we’re getting from Jonathan Golub, chief U.S. equity strategist at Credit Suisse. Golub’s point is based on data. As he sees it, “The data looks a lot less recessionary that it did three or four months ago... The things [consumers] buy aren't going to go up as much as their wages and yet jobs are really plentiful, and when you add that all together, it means a consumer is strong and if the consumer is stronger, the likelihood of a recession in the next six months or so is less than everybody thought it would be.” If Golub is right, then now is a logical time for investors to start buying into stocks, taking advantage of low prices before a market surge. Golub's colleagues at Credit Suisse are following this upbeat train of thought, and picking out the stocks that are primed for gains should conditions turn bullish. Do other analysts agree with Credit Suisse? We’ve opened the TipRanks database to find out. Here’s the lowdown. Viridian Therapeutics, Inc. (VRDN) We'll start with Viridian Therapeutics, a biopharma firm with a focus on the development of new medications for the treatment of serious and rare diseases with high unmet medical needs. Viridian is working with drug candidates that are potentially best-in-class, and its leading candidates target thyroid eye disease (TED). The company’s preclinical research program is focused on rare and autoimmune disorders. The leading drug candidates, however, are worth a closer look. VRDN-001 is currently the subject of the recently initiated Phase 3 THRIVE trial; last month, Viridian announced the first patient enrollment in the trial, which will be conducted in some 50 sites across both North America and Europe. The trial will evaluate the efficacy and safety of VRDN-100 as a treatment for patients with active TED. Topline results are anticipated for release in mid-2024. Story continues The company is also evaluating VRDN-001 in a Phase 1/2 trial, which includes multiple randomized, placebo-controlled cohorts of both normal healthy volunteers and TED patients. Initial clinical data from the first cohort suggested significant and rapid improvements in both signs and symptoms of TED at week 6 after two infusions of 10 mg/kg VRDN-001. More significantly, patients enrolled in the 20 mg/kg cohort had baseline characteristics that were generally similar to the 10mg/kg cohort. Among the bulls is Credit Suisse analyst Tiago Fauth who takes a bullish stance on COGT shares. He writes, "We believe the company’s current market cap undervalues the overall long-term outlook for Viridian, underpinned by: (1) a lead asset with well-characterized safety, pharmacokinetic/ pharmacodynamics (PK/PD), a validated mechanism of action, and the potential for differentiated efficacy/dosing regimen; (2) a validated multibillion-dollar end market; (3) multiple opportunities for a potential best-in-class subcutaneous product; and (4) strong balance sheet offering visibility into registrational data points.” At the bottom line, Fauth rates VRDN as Outperform (i.e. Buy), and his price target, set at $51, suggests an upside of ~75% by the end of 2023. (To watch Fauth’s track record, click here) Some stocks make a roundly positive impression on Wall Street’s analysts, and VRDN is one of those. This biopharma company has a unanimous Strong Buy consensus rating, based on 11 recent positive reviews. (See VRDN stock forecast on TipRanks) CNH Industrial N.V. (CNHI) The next Credit Suisse pick we're looking at is CNH Industrial, a player in the agriculture and construction service and equipment fields. The UK-based company provides world-class heavy equipment for large-scale farming and construction, along with R&D capabilities and strategic direction. CNHI operates through several subsidiaries, and known for holding major brand names in its field, including Case IH, New Holland, and Steyr. The company finished 3Q22, the last reported quarter, with consolidated revenues of $5.88 billion, for a 23% year-over-year gain, while net income rose 21% y/y to reach $559 million. At the bottom line, the diluted EPS of 41 cents represented a y/y gain of 20%, and beat the forecast by 24%. CNHI saw $272 million in net cash from operations during the quarter. The agricultural segment proved stronger than construction during the past year, with agriculture accounting for $4.5 billion of Q3’s net sales, a gain of 26% from the prior-year quarter. Construction sales, at $895 million, were up 16% y/y. Fluctuations in currency valuations helped make 2022 a tough year for CNHI, but despite the foreign exchange headwinds, the company is predicting a 16% to 18% full-year gain in net sales for industrial activities. Covering CNHI for Credit Suisse, 5-star analyst Jamie Cook likes what he sees in the company’s prospects for continued growth. “By 2024, CNHI targets Industrial Activities net sales of $20- 22B, representing a ~6% CAGR, and adjusted EBIT margins of 12-13%. CNHI expects to gain market share by more than 200bps over the three-year planning period (2022-24), driven by new product launches, and assumes minimal volume growth from the Farm Equipment market. Given our bullish view on AG fundamentals and our view that Precision AG is accretive to margins, we believe CNHI’s targets are reasonable and have potential upside," Cook noted. Cook’s optimism backs up her Outperform (i.e. Buy) rating on CNHI, while her $21 price target shows her confidence in a 30% one-year upside potential for the shares. (To watch Cook’s track record, click here) Overall, CNHI has 12 recent analyst reviews on record, and their 9 to 3 breakdown, favoring Buys over Holds, gives it a Strong Buy consensus rating. (See CNHI stock forecast on TipRanks) Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

NEWS_513

CNH Industrial (CNHI) closed at $16.92 in the latest trading session, marking a +0.53% move from the prior day. The stock lagged the S&P 500's daily gain of 1.29%. Elsewhere, the Dow gained 0.8%, while the tech-heavy Nasdaq added 10.96%. Prior to today's trading, shares of the truck, tractor and bus maker had gained 3.63% over the past month. This has outpaced the Auto-Tires-Trucks sector's loss of 14.95% and the S&P 500's loss of 0.23% in that time. CNH Industrial will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.35, up 40% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $6.29 billion, down 30.64% from the year-ago period. Investors might also notice recent changes to analyst estimates for CNH Industrial. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.32% lower within the past month. CNH Industrial is holding a Zacks Rank of #3 (Hold) right now. In terms of valuation, CNH Industrial is currently trading at a Forward P/E ratio of 10.52. For comparison, its industry has an average Forward P/E of 6.75, which means CNH Industrial is trading at a premium to the group. The Automotive - Foreign industry is part of the Auto-Tires-Trucks sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 22% of all 250+ industries. Story continues The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CNH Industrial N.V. (CNHI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_514

NORTHAMPTON, MA / ACCESSWIRE / January 10, 2023 / The New Holland T7 Methane Power LNG Pre-Production Prototype arrives through the strength of CNH Industrial's partnerships with experts in clean energy. Our work with Bennamann, a UK-based expert in solutions to capture and repurpose fugitive methane emissions for energy use, means this new tractor comes not only equipped with cutting edge technology, but a tried and tested solution to create full energy independence on the farm and bring sustainable benefits to customers. Bennamann has been researching and developing biomethane production for over a decade. In Cornwall, UK, the company has been working closely with the county's farming community to develop alternative fuels solutions of a global significance. In September 2020, Cornwall Council approved the investment of £1.58 million into a multi-farm pilot project spearheaded by Bennamann to trial the production, aggregation and sale of biomethane fuels made from cow manure slurry. It was a landmark decision that opened the door to the testing of innovation on farm and in field. The first farm in the pilot was Trenance Farm, located near Saltash, the gateway to rural Cornwall. It is here that the T7 Methane Power LNG Pre-Production Prototype has been put through its paces and had its functionality within a sustainable, energy independent farm proven. An Important Pilot Project The pilot is installing Bennamann's proprietary sealed slurry lagoon-based biogas capture technology on each farm. The gas captured at each lagoon is temporarily stored above its surface until processed using a newly developed, highly innovative, mobile version of Bennamann's novel small-scale BioCycle unit. The resulting biomethane can then be used in a number of ways. Some is being sold to Corserv, a highways, engineering and construction specialist (wholly owned by the Cornwall Council) also involved in the pilot. It is using the fuel generated to introduce low emissions vehicles into its vehicle fleet. Portions are also being converted into electricity to power the farms. Additionally, the process results in a 100% natural fertilizer as a by-product for use on farm. Story continues The pilot is of significant benefit to the environment. The CO 2 reduction for a 120-cow farm could, for example, be equivalent to around 100 western households, helping Cornwall become carbon neutral by 2030. On the Ground at Trenance Farm The farm that began the pilot was Trenance Farm, which spans 134 acres of grassland, with 110 Friesian-cross dairy cows. It is run by Katie and Kevin Hoare who both come from dairy farming families and, like all the pilot farm farmers, are tenants of Cornwall Council. The new slurry lagoon and on-site plant room containing the biogas filtration system and slurry handling pumps was commissioned in late 2021. Shortly after which it began producing vehicle grade fugitive methane through Bennamann's mobile BioCycle unit. This fuel is being sent to Corserv and also used to power Bennamann's own company truck. Crucially, though, it has recently been used to support field testing of the T7 Methane Power LNG Pre-Production Prototype. Katie Hoare says, "Environmentally, short term there are a lot of benefits, it has improved our soil health and grass growth and long term there will be more gains to be had. There are quite a few other dairy farms in the area that are very similar to us and if we can make it work, anyone can make it work." Trenance Farm will go down in history as the first commercial farm with Bennamann's methane solution fully functional. Katie and Kevin Hoare have been crucial enablers in the realization of this project and are now starting to reap the benefits of an innovative energy independent farm. They have started to see environmental, financial and operational impacts and are benefiting from increased sustainability across their entire business. More updates from CNH Industrial Tech Day are to follow on 3BL. #CNHIndustrial #BreakingNewGround #Tech #TechDay2022 CNH Industrial, Tuesday, January 10, 2023, Press release picture New Holland T7 Methane Power LNG Tractor View additional multimedia and more ESG storytelling from CNH Industrial on 3blmedia.com. Contact Info: Spokesperson: CNH Industrial Website: https://www.3blmedia.com/profiles/cnh-industrial Email: info@3blmedia.com SOURCE: CNH Industrial View source version on accesswire.com: https://www.accesswire.com/734755/In-the-Field-With-Bennamann-the-New-Holland-T7-Methane-Power-LNG-Prototype

NEWS_515

CNH Industrial N.V. CASE_ IH_Patriot_50_Series_ Sprayer New_Holland_Straddle_Tractor_concept New_Holland_TK_Methane_Power_vineyard_crawler_tractor London, January 12, 2023 Case IH and New Holland, global agricultural brands of CNH Industrial, have been awarded 2022 Good Design Awards. The Case IH Patriot® 50 series sprayer and New Holland’s Straddle Tractor Concept and TK4 Tractor received recognition. Case IH’s Patriot 50 series sprayer is designed to help farmers work more productively and efficiently. From the comfort of the well-appointed cab, the operator has complete control of the vehicle’s advanced connectivity solutions and integrated spray technology. The latter produces reports on the vehicle’s spray rates which allows operators to accurately calculate input prices. New Holland’s Straddle Tractor Concept was realized in collaboration with renowned automotive design house Pininfarina. It satisfies the requirements posed when working in narrow vineyards. Its futuristic design, combining form and function, has also been created as ready for electric traction demonstrating New Holland’s commitment to more productive and sustainable agriculture. New Holland and FPT Industrial’s TK4 Methane Power vineyard crawler tractor blends style, function, and sustainability. It is powered by the FPT Industrial F28 engine which runs on biomethane. CNH Industrial is committed to making agribusiness ever more efficient and sustainable. Our partnerships with industry-leading innovators help us to achieve this goal. The Good Design Awards are organized by the Chicago Athenaeum Museum of Architecture and Design and Metropolitan Arts Press Ltd. They recognize the most innovative and cutting-edge industrial, product, and graphic designs produced around the world. The selection criteria are based on the highest aesthetic in terms of innovative design, new technologies, form, materials, construction, concept, function, utility, energy efficiency, and sensitivity to the environment. Story continues Building products worthy of such prestigious awards once again demonstrates our commitment to excellence in design and innovation for the world’s farmers. CNH Industrial (NYSE: CNHI / MI: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland Agriculture supply 360° agriculture applications from machines to implements and the digital technologies that enhance them; and CASE and New Holland Construction Equipment deliver a full lineup of construction products that make the industry more productive. The Company’s regionally focused Brands include: STEYR, for agricultural tractors; Raven, a leader in digital agriculture, precision technology and the development of autonomous systems; Flexi-Coil, specializing in tillage and seeding systems; Miller, manufacturing application equipment; Kongskilde, providing tillage, seeding and hay & forage implements; and Eurocomach, producing a wide range of mini and midi excavators for the construction sector, including electric solutions. Across a history spanning over two centuries, CNH Industrial has always been a pioneer in its sectors and continues to passionately innovate and drive customer efficiency and success. As a truly global company, CNH Industrial’s 37,000+ employees form part of a diverse and inclusive workplace, focused on empowering customers to grow, and build, a better world. For more information and the latest financial and sustainability reports visit: cnhindustrial.com For news from CNH Industrial and its Brands visit: media.cnhindustrial.com Media contacts: Rebecca Fabian Anna Angelini North America United Kingdom Tel. +1 312 515 2249 Tel. +44 (0)7725 826 007 mediarelations@cnhind.com Attachments

NEWS_516

Canadian National Railway Company MONTREAL, Jan. 09, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) will issue its fourth-quarter and full-year 2022 financial and operating results after the market close on January 24, 2023. CN's senior officers will review the results and the railway's outlook in a conference call starting at 4:30 p.m. Eastern Time on January 24. Tracy Robinson, CN President and Chief Executive Officer, will lead the call. Parties wishing to participate via telephone may dial 1-800-806-5484 (Canada/U.S.), or 1-416-340-2217 (International), using 9915772# as the passcode. Participants are advised to dial in 10 minutes prior to the call. CN will webcast the presentation live and furnish slides supporting the officers' remarks via the Investors section of its website at www.cn.ca/en/investors. A webcast replay will be available after the call ends. About CN CN is a world-class transportation leader and trade-enabler. Essential to the economy, to the customers, and to the communities it serves, CN safely transports more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year. As the only railroad connecting Canada’s Eastern and Western coasts with the U.S. South through a 18,600-mile rail network, CN and its affiliates have been contributing to community prosperity and sustainable trade since 1919. CN is committed to programs supporting social responsibility and environmental stewardship. Contacts: Media Investment Community Jonathan Abecassis Paul Butcher Senior Manager, Media Relations Vice-President (438) 455-3692 Investor Relations media@cn.ca (514) 399-0052 investor.relations@cn.ca

NEWS_517

Canadian National Railway Company Collective Agreement Ratified Before End of Previous Agreement MONTREAL, Jan. 03, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that on December 23, 2022, the Teamsters Canada Rail Conference ratified a new collective agreement. The agreement covers approximately 160 rail traffic controllers in Canada. “We are pleased to have negotiated a new collective agreement before the expiry of the previous one. We are committed to working with our railroaders and their union representatives to create a workplace where employees thrive and together, we deliver better and safer service to our valued customers.” Tracy Robinson, President and Chief Executive Officer, CN The agreement came into effect on January 1, 2023 and includes adjustments to wages of 3% in 2023, 3% in 2024 and 2.5% in 2025 and other benefits. The agreement is in effect until December 31, 2025. About CN CN is a world-class transportation leader and trade-enabler. Essential to the economy, to the customers, and to the communities it serves, CN safely transports more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year. As the only railroad connecting Canada’s Eastern and Western coasts with the U.S. South through a 18,600-mile rail network, CN and its affiliates have been contributing to community prosperity and sustainable trade since 1919. CN is committed to programs supporting social responsibility and environmental stewardship. Contacts: Media Investment Community Jonathan Abecassis Paul Butcher Senior Manager Vice-President Media Relations Investor Relations 438-455-3692 media@cn.ca (514) 399-0052 investor.relations@cn.ca

NEWS_518

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. Spare a thought for those who held Cinemark Holdings, Inc. (NYSE:CNK) for five whole years - as the share price tanked 76%. And some of the more recent buyers are probably worried, too, with the stock falling 51% in the last year. More recently, the share price has dropped a further 31% in a month. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Check out our latest analysis for Cinemark Holdings Cinemark Holdings isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. In the last five years Cinemark Holdings saw its revenue shrink by 18% per year. That's definitely a weaker result than most pre-profit companies report. So it's not altogether surprising to see the share price down 12% per year in the same time period. This kind of price performance makes us very wary, especially when combined with falling revenue. Of course, the poor performance could mean the market has been too severe selling down. That can happen. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). Cinemark Holdings is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts What About The Total Shareholder Return (TSR)? We've already covered Cinemark Holdings' share price action, but we should also mention its total shareholder return (TSR). Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. Cinemark Holdings' TSR of was a loss of 74% for the 5 years. That wasn't as bad as its share price return, because it has paid dividends. Story continues A Different Perspective We regret to report that Cinemark Holdings shareholders are down 51% for the year. Unfortunately, that's worse than the broader market decline of 18%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 12% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Cinemark Holdings . But note: Cinemark Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_519

Definitive Documentary on the Legendary Comedian Hits Theaters Nationwide on February 6th for One Day Only DENVER, Jan. 6, 2023 /PRNewswire/ -- Facing the Laughter: Minnie Pearl delves into the life of groundbreaking female comedian Sarah Cannon and her humorous alter ego – Minnie Pearl. With her signature "How-deee" greeting and price tag dangling from her straw hat, Minnie Pearl became a country culture icon who was actually far different from the serious and well-educated woman who created her. Facing The Laughter: Minnie Pearl View Trailer HERE. Born Sarah Ophelia Colley Cannon, Minnie Pearl rose to fame as a comedic performer on the Grand Ole Opry, where she became known for her hilarious sketches, self-deprecating wit, and trademark catchphrase. Despite her success, Pearl faced many challenges throughout her life, including personal tragedy and the changing tides of the entertainment industry. Exclusive to the Fathom Events' presentation are country stars Kathy Mattea, Rodney Crowell and Ketch Secor, gathering in an intimate setting, to swap stories about their personal experiences with Minnie Pearl – and with Sarah Cannon. Tickets are on sale now at Fathom Events or at participating theater box offices. For a complete list of theater locations, visit www.fathomevents.com (theaters are subject to change). "Sarah Cannon (aka Minnie Pearl) left an indelible mark in country music and beyond. What a privilege to share her story," said "Facing the Laughter" producer Barb Hall. "She created her own path that left a legacy of laughter, gratitude and goodwill for those who followed to 'pay forward.' My hope is that audiences will be intrigued by her story and want to learn more." "Facing the Laughter: Minnie Pearl" delves into Pearl's humble beginnings, her rise to stardom, and her lasting impact on the world of comedy and country music. Featuring rare archival footage and interviews with those who knew her best, "Facing the Laughter: Minnie Pearl" is a heartfelt and entertaining tribute to a true American icon. Story continues The film features interviews with the Colley family (Pearl's relatives) as well as Minnie's friends and colleagues including country stars Garth Brooks, Barbara Mandrell, Bill Anderson, k.d. lang, Brenda Lee, Reba McEntire, Jeannie Seely, Pam Tillis, Tanya Tucker, Chely Wright, Dwight Yoakam along with Alabama's Teddy Gentry and Randy Owen. Fellow comedians interviewed in the documentary are Henry Cho, Trae Crowder (The Liberal Redneck), Ray Stevens, actor Paul Reubens, "Hee Haw" star Barbi Benton and more. "After Ken Burns' 'Country Music' series – which was enormously popular on Nashville Public Television – we realized that there were many stories within his series that deserved full-length documentaries. The story of Minnie Pearl was one of them," said Becky Magura, Nashville Public Television's president and CEO. "Minnie Pearl was one of the most beloved and popular figures in country music and NPT is honored to be share her groundbreaking story." About Fathom Events Fathom Events is a recognized leader in the entertainment industry as one of the top distributors of content to movie theaters in North America. Owned by AMC Entertainment Inc. (NYSE: AMC); Cinemark Holdings, Inc. (NYSE: CNK); and Regal, a subsidiary of the Cineworld Group (LSE: CINE.L), Fathom operates the largest cinema distribution network, delivering a wide variety of programming and experiences to cinema audiences in all the top U.S. markets and to more than 45 countries. For more information, visit FathomEvents.com . About Nashville Public Television: Nashville Public Television, Nashville's PBS station, is available free and over-the-air to nearly 2.4 million people throughout the Middle Tennessee and southern Kentucky viewing area. NPT's four broadcast channels are NPT, the main channel; secondary channel NPT2 (WORLD Channel); NPT3, a 24/7 PBS Kids channel; and NPT4 (Create TV). NPT is also available to anyone in the world through its array of NPT digital services, including wnpt.org, YouTube channels and the PBS video app. NPT provides, through the power of traditional television and interactive digital communications, quality educational, cultural and civic experiences that address issues and concerns of the people of the Nashville region, and which thereby help improve the lives of those we serve. Join the conversation at facebook.com/nashvillepublictelevision, on Twitter @npt8 and on Instagram @nashvillepubtv. Fathom Events (PRNewsfoto/Fathom Events) Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fathom-events-and-nashville-public-television-announce-the-release-of-facing-the-laughter-minnie-pearl-301715639.html SOURCE Fathom Events

NEWS_520

The film, underscoring the plights of pilgrims in search of healing, premieres February 8 and 9 MADRID, Jan. 3, 2023 /PRNewswire/ -- Fathom Events, in partnership with Bosco Films and Distrib Films US, announces the U.S. debut of Lourdes, coming to over 700 theaters nationwide on February 8 and 9. The documentary tells the compelling stories of six fragile pilgrims each in search of a miracle at Our Lady of Lourdes, a sanctuary in the south of France that has drawn thousands of travelers daily since the first apparition of the Blessed Virgin Mary in 1858. Lourdes While numerous made-for-television dramas, feature films, and special reports have been made about the grotto in the breathtakingly beautiful mountain town, Lourdes is the first and only documentary to take a closer look at the pilgrims. View Trailer HERE The film's directors, Thierry Demaizère and Alban Teurlai, were inspired to pursue the project after listening to an account of a friend who had recently visited Lourdes. "To our great surprise, there has not been a film made about the pilgrims, nothing that follows their steps–why they come, what they expect, what Our Lady represents for them," observed Demaizère and Teurlai. "We knew immediately that this was a story that needed to be told and can't wait for people to see it in theaters." The pilgrims profiled in the documentary, along with their caregivers, represent an interesting cross-section of humanity– accident victims, the terminally ill, an overweight and bullied teenager, and more. They all offer an alchemy of suffering, hope, and joy, from diverse backgrounds of religious faith in the face of profound tribulation. Dr. Alessandro de Franciscis, MD, a devout Catholic and a practicing physician for more than 40 years, is featured in bonus content that exclusively accompanies the theatrical release of Lourdes in the U.S. As the President of the Lourdes Office of Medical Observations since 2009, he is tasked with overseeing the medical analyses of alleged cures for those who drink and get washed of the waters of Lourdes - evaluating them according to a rubric that is both rigorous and rational. Story continues "While only 70 cases to date have been declared miraculous by the church, more than 7,000 cases of unexplained cures have been investigated medically and scientifically. There is a vulnerable human person behind every one of these cases, and Lourdes fixes its gaze at some of these remarkable stories," notes Dr. de Franciscis. "In the face of such suffering in terms of sickness, handicap, and deformity, audiences will see that there is also joy. The liturgies and daily processions at Lourdes are signs of this and of our communion as Catholics, as disciples of Jesus and common sons and daughters of his Mother." Nominated for Best Documentary at the César Awards of the French Film Academy and at the prestigious DOCVILLE Awards, Lourdes can be seen in French with English subtitles on February 8 and in Spanish with English subtitles on February 9. Tickets are on sale now at Fathom Events or at participating theater box offices. For a complete list of theater locations, visit www.fathomevents.com (theaters are subject to change). Martha Calderón, spokesperson for Bosco Films, and Dr. Alessandro de Franciscis are available for interviews in English and Spanish. Media Contacts: Carrie Kline Mission Advancement Partners carriek@revolutionizingmissions.com Colette Carey Fathom Events ccarey@fathomevents.com About Fathom Events Fathom Events is a recognized leader in the entertainment industry as one of the top distributors of content to movie theaters in North America. Owned by AMC Entertainment Inc. (NYSE: AMC); Cinemark Holdings, Inc. (NYSE: CNK); and Regal, a subsidiary of the Cineworld Group (LSE: CINE.L), Fathom operates the largest cinema distribution network, delivering a wide variety of programming and experiences to cinema audiences in all the top U.S. markets and to more than 45 countries. For more information, visit FathomEvents.com . About Bosco Films Born in 2017, Bosco Films seeks films of high artistic quality, with stories that defend human values. Its interest is cinema that invites you to grow and bring out the best in everyone, cinema that leaves a mark on the viewer like the most robust of trees: fresh, alive and at the same time remains firm in the face of the passage of time. For more information, visit https://www.boscofilms.es/. About Distrib Films US Distrib Films US is a company with years of industry experience both in Europe and the US. Distrib Films US' goal is to establish itself as one of the leading distributors of high-quality French and European films in the US. For more information, visit https://www.distribfilmsus.com/ . Fathom Events (PRNewsfoto/Fathom Events) Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fathom-events-brings-emotionally-stirring-documentary-lourdes-to-theaters-nationwide-301712680.html SOURCE Fathom Events

NEWS_521

The price-to-earnings (P/E) multiple enjoys wide-scale popularity among investors seeking stocks trading at a bargain. In addition to being a widely-used tool for screening stocks, P/E is a popular metric to work out the fair market value of a firm. But even this ubiquitously used valuation multiple has a few downsides. Although P/E is the most popular valuation metric, a more complicated multiple called EV-to-EBITDA works even better. Often considered a better alternative to P/E, it gives the true picture of a company’s valuation and earning potential, and has a more complete approach to valuation. While P/E considers a firm’s equity portion, EV-to-EBITDA determines its total value. Jackson Financial Inc. JXN, AAR Corp. AIR, Core & Main, Inc. CNM, Aegon N.V. AEG and Cowen Inc. COWN are some stocks with impressive EV-to-EBITDA ratios. Is EV-to-EBITDA a Better Substitute to P/E? EV-to-EBITDA is the enterprise value (EV) of a stock divided by its earnings before interest, taxes, depreciation and amortization (EBITDA). EV is the sum of a company’s market capitalization, its debt and preferred stock minus cash and cash equivalents. The other component of the multiple, EBITDA, gives a better idea of a company’s profitability as it removes the impact of non-cash expenses like depreciation and amortization that reduce net earnings. It is also often used as a proxy for cash flows. Typically, the lower the EV-to-EBITDA ratio, the more attractive it is. A low EV-to-EBITDA ratio could signal that a stock is potentially undervalued. EV-to-EBITDA takes into account the debt on a company’s balance sheet that the P/E ratio does not. Due to this reason, EV-to-EBITDA is generally used to value the potential acquisition targets as it shows the amount of debt the acquirer has to assume. Stocks boasting a low EV-to-EBITDA multiple could be seen as attractive takeover candidates. Another shortcoming of P/E is that it can’t be used to value a loss-making firm. A company’s earnings are also subject to accounting estimates and management manipulation. On the other hand, EV-to-EBITDA is difficult to manipulate and can also be used to value companies making losses but are EBITDA-positive. EV-to-EBITDA is also a useful yardstick for measuring the value of firms that are highly leveraged and have a high degree of depreciation. Moreover, it can be used to compare companies with different levels of debt. But EV-to-EBITDA has its limitations too. The ratio varies across industries (a high-growth industry typically has a higher multiple and vice versa) and is usually not appropriate while comparing stocks in different industries, given their diverse capital requirements. Hence, a strategy entirely based on EV-to-EBITDA might not yield the desired results. But you can club it with other major ratios such as price-to-book (P/B), P/E and price-to-sales (P/S) to screen bargain stocks. Story continues Screening Criteria Here are the parameters to screen for bargain stocks: EV-to-EBITDA 12 Months-Most Recent less than X-Industry Median: A lower EV-to-EBITDA ratio represents a cheaper valuation. P/E using (F1) less than X-Industry Median: This metric screens stocks that are trading at a discount to their peers. P/B less than X-Industry Median: A lower P/B compared with the industry average implies that the stock is undervalued. P/S less than X-Industry Median: The lower the P/S ratio, the more attractive the stock is, as investors will have to pay a smaller price for the same amount of sales generated by the company. Estimated One-Year EPS Growth F(1)/F(0) greater than or equal to X-Industry Median: This parameter will help in screening stocks that have growth rates higher than the industry median. This is a meaningful indicator as decent earnings growth always adds to investor optimism. Average 20-day Volume greater than or equal to 100,000: The addition of this metric ensures that shares can be traded easily. Current Price greater than or equal to $5: This parameter will help in screening stocks that are trading at a minimum price of $5 or higher. Zacks Rank less than or equal to 2: No screening is complete without the Zacks Rank, which has proven its worth since inception. It is a fundamental truth that stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have always managed to beat adversities and outperform the market. Value Score of less than or equal to B: Our research shows that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential. Here are our five picks out of the nine stocks that passed the screen: Jackson Financial is a financial services company offering a diverse suite of annuities to retail investors in the United States. This Zacks Rank #1 stock has a Value Score of A. Jackson Financial has an expected earnings growth rate of 20.3% for 2023. The Zacks Consensus Estimate for JXN’s 2023 earnings has been revised 6.3% upward over the past 60 days. AAR provides various products and services to the aviation and defense industries worldwide. AIR, a Zacks Rank #1 stock, has a Value Score of B. You can see the complete list of today’s Zacks #1 Rank stocks here. AAR has an expected year-over-year earnings growth rate of 27.3% for fiscal 2023. The Zacks Consensus Estimate for AIR’s fiscal 2023 earnings has been revised 2.4% upward over the last 60 days. Core & Main is a leading specialized distributor of water, wastewater, storm drainage and fire protection products, and related services. This Zacks Rank #2 stock has a Value Score of A. Core & Main has an expected year-over-year earnings growth rate of 159% for the current fiscal year. The consensus estimate for CNM’s current fiscal-year earnings has been revised 10.8% upward over the last 60 days. Aegon is an integrated international financial services group offering investment, protection and retirement solutions. This Zacks Rank #2 stock has a Value Score of A. Aegon has an expected year-over-year earnings growth rate of 1,625% for 2023. The Zacks Consensus Estimate for AEG’s 2023 earnings has been revised 1.5% upward over the last 60 days. Cowen provides investment banking, equity research, sales and trading, prime brokerage, global clearing, commission management services and actively managed alternative investment products globally. This Zacks Rank #2 stock has a Value Score of A. Cowen has an expected earnings growth rate of 69.8% for 2023. The consensus estimate for COWN’s 2023 earnings has been revised 0.2% upward over the past 60 days. You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aegon NV (AEG) : Free Stock Analysis Report AAR Corp. (AIR) : Free Stock Analysis Report Cowen Group, Inc. (COWN) : Free Stock Analysis Report Core & Main, Inc. (CNM) : Free Stock Analysis Report Jackson Financial Inc. (JXN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_522

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. With that in mind, we've noticed some promising trends at Core & Main (NYSE:CNM) so let's look a bit deeper. Understanding Return On Capital Employed (ROCE) For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for Core & Main: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.18 = US$767m ÷ (US$5.2b - US$987m) (Based on the trailing twelve months to October 2022). Thus, Core & Main has an ROCE of 18%. That's a relatively normal return on capital, and it's around the 16% generated by the Trade Distributors industry. View our latest analysis for Core & Main roce Above you can see how the current ROCE for Core & Main compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like to see what analysts are forecasting going forward, you should check out our free report for Core & Main. What Can We Tell From Core & Main's ROCE Trend? The trends we've noticed at Core & Main are quite reassuring. Over the last two years, returns on capital employed have risen substantially to 18%. The amount of capital employed has increased too, by 30%. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed. The Bottom Line On Core & Main's ROCE In summary, it's great to see that Core & Main can compound returns by consistently reinvesting capital at increasing rates of return, because these are some of the key ingredients of those highly sought after multi-baggers. Astute investors may have an opportunity here because the stock has declined 27% in the last year. That being the case, research into the company's current valuation metrics and future prospects seems fitting. Story continues On a separate note, we've found 2 warning signs for Core & Main you'll probably want to know about. If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_523

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Splunk SPLK: This company that provides software solutions that enable enterprises to gain real-time operational intelligence by harnessing the value of their data, has seen the Zacks Consensus Estimate for its next year earnings increasing 73.1% over the last 60 days. Splunk Inc. Price and Consensus Splunk Inc. Price and Consensus Splunk Inc. price-consensus-chart | Splunk Inc. Quote Richardson Electronics RELL: This company which is a global provider of Engineered Solutions, serving the RF, Wireless & Power Conversion; Electron Device; Security; and Display Systems markets, has seen the Zacks Consensus Estimate for its current year earnings increasing 20.6% over the last 60 days. Richardson Electronics, Ltd. Price and Consensus Richardson Electronics, Ltd. Price and Consensus Richardson Electronics, Ltd. price-consensus-chart | Richardson Electronics, Ltd. Quote Core & Main CNM: This company which specializes in distribution of water, wastewater, storm drainage and fire protection products, and related services, to municipalities, private water companies and professional contractors across municipal, non-residential and residential end markets, has seen the Zacks Consensus Estimate for its current year earnings increasing 10.8% over the last 60 day. Core & Main, Inc. Price and Consensus Core & Main, Inc. Price and Consensus Core & Main, Inc. price-consensus-chart | Core & Main, Inc. Quote IBEX Limited IBEX: This CX solutions company that provides end-to-end technology-enabled customer lifecycle experience solutions in the United States and internationally, has seen the Zacks Consensus Estimate for its current year earnings increasing 2.8% over the last 60 days. IBEX Limited Price and Consensus IBEX Limited Price and Consensus IBEX Limited price-consensus-chart | IBEX Limited Quote StoneX Group SNEX: This financial services company that offers execution, post-trade settlement, clearing and custody services, has seen the Zacks Consensus Estimate for its current year earnings increasing 2.5% over the last 60 days. Story continues StoneX Group Inc. Price and Consensus StoneX Group Inc. Price and Consensus StoneX Group Inc. price-consensus-chart | StoneX Group Inc. Quote You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Richardson Electronics, Ltd. (RELL) : Free Stock Analysis Report Splunk Inc. (SPLK) : Free Stock Analysis Report StoneX Group Inc. (SNEX) : Free Stock Analysis Report IBEX Limited (IBEX) : Free Stock Analysis Report Core & Main, Inc. (CNM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_524

Shares of Core & Main (CNM) have gained 0.4% over the past four weeks to close the last trading session at $20.76, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.56 indicates a potential upside of 32.8%. The mean estimate comprises nine short-term price targets with a standard deviation of $5.73. While the lowest estimate of $22 indicates a 6% increase from the current price level, the most optimistic analyst expects the stock to surge 97.5% to reach $41. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. But, for CNM, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside. Price, Consensus and EPS Surprise Zacks Price, Consensus and EPS Surprise Chart for CNM Here's What You May Not Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why? Story continues They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts. However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces. That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism. Why CNM Could Witness a Solid Upside There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The Zacks Consensus Estimate for the current year has increased 11.2% over the past month, as three estimates have gone higher compared to no negative revision. Moreover, CNM currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much CNM could gain, the direction of price movement it implies does appear to be a good guide. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Core & Main, Inc. (CNM) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_525

LARGO, Fla., January 09, 2023--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the fourth quarter 2022 after the market close on Thursday, February 2, 2023. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release and the associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks posed to the Company’s business, financial condition, and results of operations by the COVID-19 global pandemic and the various government and other responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability, as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2021, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and listed in the Current Report filed on Form 8-K on November 15, 2022. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. Story continues View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005695/en/ Contacts CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 ToddGarner@conmed.com

NEWS_526

~ Expands the Foley-led Partnership Strategy of Multi-Club Ownership to Develop a Distinct Global Football Asset Portfolio ~ LAS VEGAS, January 13, 2023--(BUSINESS WIRE)--Cannae Holdings, Inc. (NYSE: CNNE) ("Cannae" or the "Company") today announced that Black Knight Football and Entertainment, LP ("BKFE" or the "Partnership"), a partnership led by William P. Foley, II ("Foley") and majority owned by Cannae, entered into a strategic partnership and agreed to acquire a significant minority ownership interest in FC Lorient (the "Club"), a French Ligue 1 football club. The agreement provides BKFE an opportunity to invest additional capital after this season. The investment in FC Lorient advances BKFE’s multi-club ownership strategy initiated last month with the acquisition of A.F.C. Bournemouth, an English Premier League club. The Partnership is building a global network of world-class football clubs, players, and real estate assets that will produce operational synergies, accelerate player development, enable efficient player migration across BKFE’s network of owned and operated clubs, while driving both strong on-field and financial results. "We are excited to announce a strategic partnership and investment in FC Lorient today," Foley said. "Loïc Fery has successfully built a best-in-class football club and will be a great partner as we build BKFE into a leading multi-club football operator. I look forward to partnering with Loïc and his team to accelerate the success of FC Lorient and BKFE." For the last fourteen seasons, FC Lorient has operated under the leadership of Loïc Fery ("Fery"), after becoming the youngest president of a Ligue 1 club. Fery’s management has been central to the growth and development of the Club. FC Lorient will be a key contributor to, and beneficiary of, BKFE’s multi-club ownership strategy. In BKFE, FC Lorient adds an operator with a track record of success in Bill Foley, who founded the Vegas Golden Knights of the National Hockey League and recorded the most successful season for an expansion franchise in any sport, having reached the Stanley Cup Final in the inaugural season. Story continues Fery commented, "FC Lorient represents an extraordinary opportunity, which also involves great responsibilities. Since I took over the club in 2009, each of my decisions has been motivated by the objective of structuring and sustaining the club at the highest level. Ligue 1 has an ambition of excellence for French football, and I want our team to be part of this increasingly competitive future. Bill's experience and results in professional sport (notably with the Vegas Golden Knights), his passion, his determined character, and his global approach to football with Bournemouth convinced me to join forces. I am very happy to make this opportunity a reality for FC Lorient and welcome Bill to FC Lorient." FC Lorient is a fixture of Ligue 1, the top professional football league in France, having competed at the highest level of French football for 13 of the last 16 seasons. Ligue 1, which refers to itself as "The League of Talents", was a priority for BKFE as it is home to some of the best academies in Europe and is known for developing some of the most talented players in the world. FC Lorient currently sits in 6th place in Ligue 1 and has the 4th youngest roster, a testament to the Club’s ability to effectively develop and utilize its youth talent. About Cannae Holdings, Inc. We primarily acquire interests in operating companies and are engaged in actively managing and operating a core group of those companies. We are a long-term owner that secures control and governance rights of other companies primarily to engage in their lines of business and we have no preset time constraints dictating when we sell or dispose of our businesses. We believe that our long-term ownership and active involvement in the management and operations of companies helps maximize the value of those businesses for our shareholders. Cannae’s current principal holdings include Dun & Bradstreet Holdings, Inc. (NYSE: DNB), in which Cannae holds 79 Million shares or 18% interest, and Alight, Inc. (NYSE: ALIT), in which Cannae owns 52.5 Million shares representing a 10% interest. Cannae also holds 6 Million shares, or 4%, of Ceridian HCM Holdings, Inc. (NYSE: CDAY), 27 Million shares, or 24%, of System1, Inc. (NYSE: SST), and 3.4 Million shares, or 5.5% of Paysafe (NYSE: PSFE). Cannae’s other principal holdings include Sightline Payments, of which Cannae owns 32%. About FC Lorient FC Lorient is a French professional football club based in Lorient, Brittany, France. The Club was founded in 1926 and currently competes in Ligue 1, the highest level of the men’s French football league system. Lorient won the Coupe de France in 2002. FC Lorient has a successful track-record of developing world-class footballers highlighted by its robust youth academy. FC Lorient also has a leading women's section and is active in developing and promoting women's football. The Club plays its home matches at the 18,000-seat Stade Yves Allainmat ("Le Moustoir"), which host every summer the famous European Celtic Festival and serves as a multi-purpose venue, staging international sporting events as well as major concerts and shows. Forward-Looking Statements and Risk Factors This document contains forward-looking statements that involve multiple risks and uncertainties. Statements that are not historical facts, including statements regarding our expectations, hopes, intentions, or strategies regarding the future are forward-looking statements. Forward-looking statements are based on management's beliefs, as well as assumptions made by, and information currently available to, management. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. We undertake no obligation to update any forward-looking statements, resulting from new information, future events or otherwise. The risks and uncertainties which forward-looking statements are subject to include, but are not limited to: changes in general economic, business and political conditions, changes in the financial markets, and changes in the conditions resulting from the outbreak of a pandemic, such as the novel COVID-19 ("COVID-19"); the overall impact of the outbreak of COVID-19 and measures to curb its spread, including the effect of governmental or voluntary mitigation measures such as business shutdowns, social distancing, and stay-at-home orders; our potential inability to find suitable acquisition candidates, acquisitions in lines of business that will not necessarily be limited to our traditional areas of focus, or difficulties in integrating acquisitions; significant competition that our operating subsidiaries face; compliance with extensive government regulation of our operating subsidiaries; risks and limitations on our strategic and operating flexibility related to the Investment Company Act of 1940. This document should be read in conjunction with the risks detailed in the "Statement Regarding Forward-Looking Information," "Risk Factors" and other sections of the Company’s Form 10-Q,10-K and other filings with the Securities and Exchange Commission. View source version on businesswire.com: https://www.businesswire.com/news/home/20230110006030/en/ Contacts Jamie Lillis, Managing Director, Solebury Strategic Communications, 203-428-3223, jlillis@soleburystrat.com

NEWS_527

Madison Funds, managed by Madison Investment Management, released its “Madison Mid Cap Fund” fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.6% compared to a 9.2% increase in the Russell Midcap Index. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022. Madison Funds highlighted stocks like Cannae Holdings, Inc. (NYSE:CNNE) in the Q4 2022 investor letter. Based in Las Vegas, Nevada, Cannae Holdings, Inc. (NYSE:CNNE) is an investment firm. On January 12, 2023, Cannae Holdings, Inc. (NYSE:CNNE) stock closed at $23.08 per share. One-month return of Cannae Holdings, Inc. (NYSE:CNNE) was 7.90%, and its shares lost 30.52% of their value over the last 52 weeks. Cannae Holdings, Inc. (NYSE:CNNE) has a market capitalization of $1.801 billion. Madison Funds made the following comment about Cannae Holdings, Inc. (NYSE:CNNE) in its fourth-quarter 2022 investor letter: “Cannae Holdings, Inc. (NYSE:CNNE) is an investment holding company chaired by Bill Foley, who has a phenomenal 35-year track record of investing in undermanaged companies with a solid foundation and improving them. His more recent track record has not been as good as in the past, and given his advanced age, we decided that the key thesis point of relying on his long-term expertise no longer applied.” Image by MayoFi from Pixabay Cannae Holdings, Inc. (NYSE:CNNE) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 22 hedge fund portfolios held Cannae Holdings, Inc. (NYSE:CNNE) at the end of the third quarter, and which was 19 in the previous quarter. We discussed Cannae Holdings, Inc. (NYSE:CNNE) in another article and shared the list of best stocks to buy according to Angela Aldrich’s Bayberry Capital Partners. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors. Story continues Suggested Articles: Disclosure: None. This article is originally published at Insider Monkey.

NEWS_528

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. By way of learning-by-doing, we'll look at ROE to gain a better understanding of CNO Financial Group, Inc. (NYSE:CNO). Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. View our latest analysis for CNO Financial Group How Do You Calculate Return On Equity? The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for CNO Financial Group is: 36% = US$469m ÷ US$1.3b (Based on the trailing twelve months to September 2022). The 'return' is the profit over the last twelve months. That means that for every $1 worth of shareholders' equity, the company generated $0.36 in profit. Does CNO Financial Group Have A Good Return On Equity? By comparing a company's ROE with its industry average, we can get a quick measure of how good it is. Importantly, this is far from a perfect measure, because companies differ significantly within the same industry classification. As is clear from the image below, CNO Financial Group has a better ROE than the average (13%) in the Insurance industry. roe That is a good sign. Bear in mind, a high ROE doesn't always mean superior financial performance. Aside from changes in net income, a high ROE can also be the outcome of high debt relative to equity, which indicates risk. To know the 2 risks we have identified for CNO Financial Group visit our risks dashboard for free. Why You Should Consider Debt When Looking At ROE Most companies need money -- from somewhere -- to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same. Story continues Combining CNO Financial Group's Debt And Its 36% Return On Equity It's worth noting the high use of debt by CNO Financial Group, leading to its debt to equity ratio of 3.00. While no doubt that its ROE is impressive, we would have been even more impressed had the company achieved this with lower debt. Debt increases risk and reduces options for the company in the future, so you generally want to see some good returns from using it. Summary Return on equity is useful for comparing the quality of different businesses. In our books, the highest quality companies have high return on equity, despite low debt. If two companies have the same ROE, then I would generally prefer the one with less debt. But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So you might want to check this FREE visualization of analyst forecasts for the company. But note: CNO Financial Group may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_529

ConnectOne Bancorp, Inc. ENGLEWOOD CLIFFS, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today announced that it plans to release results for the fourth quarter ended December 31, 2022, before the market opens on Thursday, January 26, 2023. Management will also host a conference call and audio webcast at 10:00 a.m. ET on January 26, 2023, to review the Company's financial performance and operating results. Chairman and Chief Executive Officer Frank Sorrentino III and Chief Financial Officer William S. Burns will host the call. The conference call dial-in number is 1-201-689-8471, access code 13735159. Please dial in at least five minutes before the start of the call to register. An audio webcast of the conference call will be available to the public, on a listen-only basis, via the "Investor Relations" link on the Company's website https://www.ConnectOneBank.com or at http://ir.connectonebank.com. A replay of the conference call will be available beginning at approximately 1:00 p.m. ET on Thursday, January 26, 2023 and ending on Thursday, February 2, 2023 by dialing 1-412-317-6671, access code 13735159. An online archive of the webcast will be available following the completion of the conference call at https://www.ConnectOneBank.com or at http://ir.connectonebank.com. About ConnectOne Bancorp, Inc. ConnectOne Bancorp, Inc., is a modern financial services company that operates, through its subsidiary, ConnectOne Bank, and the Bank’s fintech subsidiary, BoeFly, Inc. ConnectOne Bank is a high-performing commercial bank offering a full suite of banking & lending products and services that focus on small to middle-market businesses. BoeFly, Inc. is a fintech marketplace that connects borrowers in the franchise space with funding solutions through a network of partner banks. ConnectOne Bancorp, Inc. is traded on the Nasdaq Global Market under the trading symbol "CNOB," and information about ConnectOne may be found at https://www.connectonebank.com. Story continues Investor Contact: William S. Burns Senior Executive VP & CFO 201.816.4474; bburns@cnob.com Media Contact: Shannan Weeks, MWW 732.299.7890: sweeks@mww.com

NEWS_530

Canadian Natural Resources (CNQ) closed at $55.18 in the latest trading session, marking a +1.19% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.08%. At the same time, the Dow lost 0.34%, and the tech-heavy Nasdaq gained 11.55%. Prior to today's trading, shares of the oil and natural gas company had lost 0.09% over the past month. This has was narrower than the Oils-Energy sector's loss of 3.23% and the S&P 500's loss of 1.03% in that time. Wall Street will be looking for positivity from Canadian Natural Resources as it approaches its next earnings report date. The company is expected to report EPS of $1.91, up 8.52% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.03 billion, down 4.33% from the year-ago period. Investors might also notice recent changes to analyst estimates for Canadian Natural Resources. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Canadian Natural Resources is currently a Zacks Rank #3 (Hold). Digging into valuation, Canadian Natural Resources currently has a Forward P/E ratio of 7.08. Its industry sports an average Forward P/E of 5.43, so we one might conclude that Canadian Natural Resources is trading at a premium comparatively. Story continues Meanwhile, CNQ's PEG ratio is currently 0.73. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Oil and Gas - Exploration and Production - Canadian was holding an average PEG ratio of 0.4 at yesterday's closing price. The Oil and Gas - Exploration and Production - Canadian industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 89, putting it in the top 36% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow CNQ in the coming trading sessions, be sure to utilize Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canadian Natural Resources Limited (CNQ) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_531

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $80.4 billion as of December 31, 2022, a decrease of $3.8 billion from assets under management at November 30, 2022. The decrease was due to market depreciation of $2.6 billion, distributions of $887 million and net outflows of $260 million. Assets Under Management (unaudited) ($ in millions) AUM Net Market AUM By investment vehicle: 11/30/2022 Flows Depreciation Distributions 12/31/2022 Institutional Accounts: Advisory $19,572 ($379) ($562) $ - $18,631 Japan Subadvisory 8,770 99 (409) (84) 8,376 Subadvisory excluding Japan 5,598 (59) (173) - 5,366 Total Institutional Accounts 33,940 (339) (1,144) (84) 32,373 Open-end Funds 38,695 76 (1,206) (662) 36,903 Closed-end Funds 11,549 3 (262) (141) 11,149 Total AUM $84,184 ($260) ($2,612) ($887) $80,425 About Cohen & Steers Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong and Tokyo. Cision View original content:https://www.prnewswire.com/news-releases/cohen--steers-announces-preliminary-assets-under-management-and-net-flows-for-december-2022-301718383.html SOURCE Cohen & Steers, Inc.

NEWS_532

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the Cohen & Steers, Inc. (NYSE:CNS) share price is up 55% in the last 5 years, clearly besting the market return of around 35% (ignoring dividends). Since the stock has added US$157m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns. Check out our latest analysis for Cohen & Steers In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During five years of share price growth, Cohen & Steers achieved compound earnings per share (EPS) growth of 15% per year. The EPS growth is more impressive than the yearly share price gain of 9% over the same period. So one could conclude that the broader market has become more cautious towards the stock. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We know that Cohen & Steers has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Cohen & Steers the TSR over the last 5 years was 102%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return. Story continues A Different Perspective Cohen & Steers shareholders are down 20% over twelve months (even including dividends), which isn't far from the market return of -19%. Longer term investors wouldn't be so upset, since they would have made 15%, each year, over five years. If the stock price has been impacted by changing sentiment, rather than deteriorating business conditions, it could spell opportunity. It's always interesting to track share price performance over the longer term. But to understand Cohen & Steers better, we need to consider many other factors. Take risks, for example - Cohen & Steers has 3 warning signs (and 2 which shouldn't be ignored) we think you should know about. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_533

Stoll’s history of success affirms the company’s commitment to growing commercial and carrier fiber solutions MATTOON, Ill., January 10, 2023--(BUSINESS WIRE)--Consolidated Communications (NASDAQ: CNSL), a leading Fiber-to-the-Premise (FttP) broadband provider, today announced Dan Stoll as president of the Company’s commercial and carrier business. Stoll will oversee Consolidated’s commercial and carrier go-to-market strategy including: sales, delivery, customer support, and related development and expansion of the Company’s fiber network. Michael Smith, who previously served as president of the commercial and carrier business, is retiring from the Company after 30 successful years of service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005126/en/ Dan Stoll, President of Commercial and Carrier Business for Consolidated Communications (Photo: Business Wire) "Dan is a recognized leader with a rich history of growth successes in the telecom and network infrastructure industry," said Bob Udell, president and chief executive officer at Consolidated. "Dan will be instrumental in further accelerating our commercial and carrier strategy and delivering a differentiated offering to our customers. His leadership successes and track record of translating fiber network investments into increased sales velocity will have a significant impact on our organic growth. I am pleased to have Dan join the Consolidated family and help drive the next phase of our growth strategy." Stoll has more than 22 years of experience in the telecommunications and fiber network infrastructure industry. Most recently, Stoll served in key senior leadership roles at Zayo including senior vice president of the west region and the managing director of regional networks. Prior to joining Zayo, Dan led several functions at Integra Telecom, which later spun off its fiber network assets into Electric Lightwave. As president of Electric Lightwave, Dan was responsible for sales, marketing, product, network intelligence, development, and the customer experience support teams. Story continues "I’m thrilled to be joining Consolidated Communications, a company that has executed soundly on its fiber network expansion and has built a platform for significant growth opportunities across its commercial and carrier channels," said Stoll. "I believe Consolidated has a strong business model that uniquely positions us to capitalize on our broadband fiber investments and continue to grow commercial and carrier data services in a cohesive and differentiated way." Stoll received a B.A. degree in business finance from Westminster College and an MBA from the University of Southern California. About Consolidated Communications Consolidated Communications Holdings, Inc. (NASDAQ: CNSL) is dedicated to moving people, businesses and communities forward by delivering the most reliable fiber communications solutions. Consumers, businesses and wireless and wireline carriers depend on Consolidated for a wide range of high-speed internet, data, phone, security, cloud and wholesale carrier solutions. With a network spanning more than 57,500 fiber route miles, Consolidated is a top 10 U.S. fiber provider, turning technology into solutions that are backed by exceptional customer support. Learn more at consolidated.com. Connect with us on social media. View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005126/en/ Contacts Jennifer Spaude, Media Relations +1 507-386-3765 jennifer.spaude@consolidated.com

NEWS_534

Study to evaluate Berubicin for the treatment of newly diagnosed and relapsed/refractory primary central nervous system lymphoma (PCNSL) or non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI) HOUSTON, Jan. 12, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated Phase 1b/2 trial evaluating the Company's novel anthracycline, Berubicin, which will be conducted at the Pomeranian Medical University (PUM) in Szczecin, Poland. The study, titled "Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas," will be a single center, single-arm, open-label Phase 1b/2 clinical trial assessing the efficacy, safety, and pharmacokinetics of Berubicin in a multidrug treatment regimen for adult patients with newly diagnosed or relapsed/refractory primary central nervous system lymphoma (PCNSL) and non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI). The primary efficacy endpoint for the study is to evaluate the safety and tolerability of Berubicin in combination with other cytostatic agents and to determine the recommended Phase 2 dose (RP2D) of Berubicin. "Based on the data seen to date, Berubicin has continued to demonstrate an overall safety profile more favorable than other known anthracyclines and we remain encouraged by its potential. We are committed to Berubicin's continued development as a much-needed oncology tool and are therefore providing the study drug to the PUM for their Phase 1b/2 clinical study. Given the unmet needs and current prognosis for CNS lymphomas, the optimal treatment strategy is to improve overall survival, to which we believe Berubicin can contribute. We look forward to further understanding the potential of Berubicin in this disease and the findings from this study," commented John Climaco, CEO of CNS Pharmaceuticals. Story continues Patients enrolled in the investigator-initiated Phase 1b/2 study will receive Berubicin in escalated doses in an accelerated model assigning one patient per cohort, which will reduce the number of patients that may be treated with sub-therapeutic doses. The purpose of the dose escalation strategy is to evaluate dose limiting toxicities (DLT) and establish the appropriate dose to utilize into Phase 2 (recommended Phase 2 dose, RP2D). The initial escalation by 40% in the next cohorts will be based on safety assessments. After completing a treatment cycle, if a patient does not have any DLTs, they can proceed to the next dose level, and additional patients can be enrolled to explore higher doses. If any patient experiences DLT, that dosing cohort will be expanded to 3 patients. If 2 patients develop DLT, the given dose will be considered toxic and the next cohort will start treatment at a dose reduced by 20%. After considering the data from the Phase 1 clinical trial in patients with CNS gliomas, treatment of patients with CNS lymphomas is planned to start with a higher initial dose of Berubicin (4.8 mg/m2). A total of up to approximately 60 patients are planned to be enrolled. The minimum participation in the study for an individual patient is approximately 21 weeks. After the end-of-treatment follow-up visit, patients will enter a post-study follow-up period of up to 3 years. Berubicin is currently being evaluated for efficacy and safety in the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer, by CNS Pharmaceuticals in an ongoing, potentially pivotal global study. For more information about the potentially pivotal Berubicin trial, visit clinicaltrials.gov and reference identifier NCT04762069. About Berubicin Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn. Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. . These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-investigator-initiated-phase-1b2-trial-to-be-conducted-at-the-pomeranian-medical-university-in-poland-301719938.html SOURCE CNS Pharmaceuticals, Inc.

NEWS_535

Live video webcast on Wednesday, January 18th at 10:00 AM ET HOUSTON, January 5, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 10:00 AM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn. Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-2023-companies-to-watch-event-301714427.html SOURCE CNS Pharmaceuticals, Inc.

NEWS_536

Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations HOUSTON, Jan. 3, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has appointed Faith L. Charles as Chair of its Board of Directors. "The depth and breadth of knowledge, experience and network that Faith brings to our Board will be invaluable to CNS Pharma. We are thrilled to welcome her and look forward to leveraging her expertise as we continue to execute on our clinical development, drive future growth and create shareholder value in the near and long term," commented John Climaco, CEO of CNS Pharmaceuticals. Ms. Charles has been a corporate transactions and securities partner at the law firm of Thompson Hine, LLP, since 2010. She currently leads Thompson Hine's Life Sciences practice and co-heads the securities practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally. Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic collaborations. Ms. Charles currently serves on the Board of Directors of Avenue Therapeutics, a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases and on the Board of Directors, Audit Committee and Nominating and Corporate Governance Committee of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases whose common stock is listed on the Nasdaq. From 2018 until October 2021, Ms. Charles served on the Board of Directors and as a member of the Audit Committee and Chair of the Compensation Committee of Entera Bio Ltd., a publicly-traded biotechnology company. Ms. Charles founded the Women in Bio Metro New York chapter and chaired the chapter for five years and served on the Women and Bio National Board for over 3 years. Ms. Charles is also a member of the Board of Red Door Community formerly Gilda's Club New York City. She has been recognized as a Life Sciences Star by Euromoney's LMG Life Sciences, has been named a BTI Client Service All-Star, and was named by Crain's New York Business to the list of 2020 Notable Women in the Law. Story continues "CNS Pharmaceuticals has continually demonstrated their dedication to GBM patients and driving their clinical development of Berubicin forward. While operated by a lean and mighty management team, they have made significant advancements and I believe are in a position to positively impact the GBM treatment space, where there remains significant unmet need. I am pleased to join the Company's Board of Directors and offer insights from experiences amassed over the course of my career to help guide their clinical development program and corporate growth," added Ms. Charles. Ms. Charles holds a JD degree from The George Washington University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio's Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Business. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn. Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-appoints-faith-l-charles-jd-as-chair-of-the-board-of-directors-301712498.html SOURCE CNS Pharmaceuticals, Inc.

NEWS_537

Leveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials MORRISVILLE, N.C., and CAMBRIDGE, Mass., ROSTOCK, Germany, and BERLIN, Jan. 9, 2023 /PRNewswire/ -- Premier Research, whose mission is to help the most innovative biotech and medtech companies take their best ideas from concept to commercialization, and Centogene N.V. [Nasdaq: CNTG], the essential life science partner for data-driven answers in rare and neurodegenerative diseases, have announced a strategic partnership to provide end-to-end support in rare disease clinical trials. The collaboration aims to improve patient identification, stratification, recruitment, and enrollment, thereby increasing the likelihood of study success. Premier Research Centogene Logo With 350 million rare disease patients worldwide affected by over 7,000 rare diseases, approximately 95% of which do not have an available treatment, there is a pressing need to accelerate trials and fast-track clinical outcomes. Inherently small patient populations coupled with the complexities of disease diagnosis create significant challenges in enrolling rare disease clinical trial participants. Combining Premier Research's deep expertise in rare disease product development with advanced insights generated from the CENTOGENE Biodatabank and multiomic reference laboratories will support the faster identification of eligible patients. "The CENTOGENE Biodatabank and multiomic-based services will enhance how we design and recruit for rare disease clinical trials," Premier Research Senior Vice President, Project Delivery Angi Robinson said. "Our foremost priority is getting lifesaving treatments safely in the hands of patients. Together, we will explore ways to more rapidly engage the right patients and customize clinical delivery to meet the unique needs of sponsors in rare disease clinical research." Many clinical trials in rare diseases are the first of their kind, requiring sponsors to charge through the unknown. With extensive experience based on more than 240 rare disease studies in the past five years, Premier Research is constantly investing in new approaches that meet the complexities of rare disease research. Story continues Like Premier Research, CENTOGENE has a history of success in rare diseases, offering rapid and reliable molecular diagnoses since 2006 while building a network of approximately 30,000 active physicians worldwide. The Company's ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is then captured in the CENTOGENE Biodatabank which currently contains nearly 700,000 patients representing over 120 highly diverse countries, more than 70% of whom are of non-European descent including a large share of pediatric cases. "At CENTOGENE, we are committed to delivering data-driven, life-changing answers to accelerate and de-risk drug discovery, development, and commercialization. Precision, advanced analysis, and access is where our Biodatabank makes a qualitative difference," CENTOGENE CEO Kim Stratton said. "In partnering with Premier Research, our first strategic CRO partner, we are extending our strategy and expanding our commercialization opportunities to provide pharma partners with yet another model to work with us. By collaborating with partners to leverage our insights, omics technologies, and deep rare disease expertise, we are shifting the paradigm to transform data into life-saving therapeutics for patients around the world." About Premier Research Premier Research, a clinical research, product development, and consulting company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it's developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions. Visit premier-research.com. About CENTOGENE CENTOGENE's mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization. Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications. By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target & drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodatabank Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases. To discover more about our products, pipeline, and patient-driven purpose, visit www.centogene.com and follow us on LinkedIn. CENTOGENE Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "project," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," and "may," are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward- looking statements. Such risks and uncertainties include, among others, negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth, execute our business strategy and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our continued ongoing compliance with covenants linked to financial instruments, our requirement for additional financing, or other factors. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE's business in general, see CENTOGENE's risk factors set forth in CENTOGENE's Form 20-F filed on March 31, 2022, with the Securities and Exchange Commission (the "SEC") and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE's specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/premier-research-and-centogene-launch-strategic-partnership-to-accelerate-and-de-risk-rare-disease-clinical-development-301716122.html SOURCE Premier Research

NEWS_538

Context Therapeutics Inc. Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6 PHILADELPHIA and BASEL, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing medicines for solid tumors, and Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, today announced that the companies are collaborating to manufacture CTIM-76, Context’s clinical development candidate. CTIM-76 is a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody targeting CLDN6 positive tumors. Under the terms of the agreement, Lonza will provide manufacturability assessment, gene and cell line construction, and process development. The drug substance will be manufactured at Lonza’s Slough (UK) site, and the drug product will be manufactured at the Stein and Visp (CH) sites. Context will leverage Lonza’s expertise in developing and manufacturing complex proteins, as well as the extensive regulatory competence and manufacturing network. Martin Lehr, CEO, Context, commented: “Bispecific antibody drug candidates targeting cancer signaling pathways pose unique challenges related to their development and manufacturing. We are delighted to entrust Lonza with manufacturing Context’s clinical development candidate, CTIM-76, to target CLDN6-positive tumors. We believe this collaboration will provide us with high-quality drug substance and drug product for clinical development and beyond.” Jennifer Cannon, Executive Vice President, Global Head of Mammalian Biologics, Lonza, added: “With the biopharmaceutical sector shifting towards more complex protein formats, it is crucial to ensure manufacturability and scalability of these novel therapies. Context has an exciting portfolio, including its CTIM-76 bispecific antibody product, that can benefit from our expertise and experience in supporting the manufacturing of complex therapeutics.” Story continues About Claudin 6 and CTIM-76 Claudin 6 (CLDN6) is differentially expressed on cancer cells with no or very low expression in normal, healthy tissue. CLDN6-enriched cancers include ovarian, endometrial, testicular, and gastric, among others. With the potential to reach a large patient population and selective expression on cancer cells, CLDN6 has emerged as an important drug target. CTIM-76 is a CLDN6 and CD3 bispecific antibody currently in preclinical development that is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CLDN6 is expressed on multiple solid tumors such as ovarian cancer, sarcoma, testicular cancer, endometrial cancer, and gastric cancer. Preclinical studies of CTIM-76 show it effectively maintains a strong tumor binding property and anti-tumor activity attributable to a synergistic effect of both CLDN6 antibody and CD3 antibody while avoiding systemic immunotoxicity commonly seen with CD3 antibodies as a drug class. CTIM-76 has the potential for convenient dosing and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. About Context Therapeutics® Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for solid tumors, with a primary focus on female cancers. The Company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development. Additionally, the company is advancing onapristone extended release (ONA-XR), a novel, first-in-class, potent, and selective progesterone receptor antagonist, currently in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancers. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on Twitter and LinkedIn. About Lonza Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry. Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With more than 17,000 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 3 billion with a CORE EBITDA of CHF 987 million in H1 2022. Find out more at www.lonza.com. Follow @Lonza on LinkedIn Follow @LonzaGroup on Twitter Context Therapeutics Contact Details Media Contact: Gina Cestari 6 Degrees 917-797-7904 gcestari@6degreespr.com Investor Relations Contact: Laine Yonker Edison Group lyonker@edisongroup.com Lonza Contact Details media@lonza.com Forward-looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the selectivity, dosing convenience, potency, binding, scalable manufacturing, and safety profile of CTIM-76, (ii) the potential benefits of the agreement, including the ability of Lonza to perform as expected and to provide Context with the necessary drug substance and drug product, (iii) the potential benefits of our product candidates, and (iv) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

NEWS_539

Context Therapeutics Inc. CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in 2023 ELONA breast cancer trial open and enrolled first patient PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors, with a primary focus on female cancers, today provided 2022 year-end updates and corporate guidance for 2023. "I am proud of the substantial progress the Context team made in 2022. We achieved key corporate milestones including nominating CTIM-76 as our Claudin 6 (CLDN6) bispecific antibody clinical candidate and delivering preliminary data in clinical trials of onapristone extended release (ONA-XR), our highly potent and selective progesterone receptor antagonist," said Martin Lehr, CEO of Context. "In 2023, we will continue to advance ONA-XR across the endometrial (OATH) and breast (SMILE and ELONA) cancer clinical trials. We expect to provide a clinical data update from the ongoing OATH Phase 2 trial in mid-2023, as well as a Phase 2 data update and Phase 1b data from the SMILE and ELONA breast cancer trials, respectively, in Q4 2023. In addition, we look forward to rapidly advancing CTIM-76 toward IND submission in Q1 2024." Key Highlights CTIM-76 nominated as CLDN6 x CD3 bispecific antibody clinical candidate During Q4 2022, Context presented preclinical data introducing CTIM-76 as a differentiated, potent, and selective CLDN6-directed immunotherapy. CLDN6 is an emerging, potentially high-value oncology target that is expressed in a broad range of cancers and CLDN6 expression is associated with a poor prognosis and diminished survival in cancer patients. The Company estimates that there are approximately 62,000 patients in the United States with CLDN6-positive metastatic cancers, including lung, ovarian, endometrial, gastric, and testicular cancers. Currently, there are no FDA-approved treatments targeting CLDN6. In cell-based assays, CTIM-76 was found to be over 1,000 times more selective for CLDN6 versus CLDN9, a structurally similar protein that unlike CLDN6 is associated with potential off-target side effects. Further, CTIM-76 was also found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BiTE) format. These data were presented during a R&D webinar hosted by Context in December 2022. IND-enabling studies are scheduled for 2023 with an IND filing to support human clinical trials expected in Q1 2024. ONA-XR ongoing Phase 2 trials show encouraging endometrial and breast cancer data Endometrial cancer (OATH trial) : Metastatic endometrial cancer is an aggressive cancer of the uterus that results in approximately 13,000 deaths per year in the United States. Current treatments are limited, with combination platinum and taxane chemotherapy being the standard of care. Clinician and patient feedback indicates a high unmet need for a novel therapeutic that provides chemotherapy-like efficacy but with fewer side effects. Initial data from a Phase 2 investigator-led clinical trial found that the combination of ONA-XR with anastrozole in progesterone receptor-positive (PR+) metastatic endometrial cancer demonstrated a 4-month progression free survival (PFS) rate of 77%, a 12-month PFS rate of 33%, and favorable safety and tolerability in patients who had failed at least one prior chemotherapy in the metastatic setting. Preliminary results suggest that ONA-XR exhibits a favorable efficacy and tolerability profile relative to chemotherapy, the standard of care, which in a similar treatment setting demonstrated a 3.8-month median PFS in the KEYNOTE-775 Phase 3 trial 1 . In the KEYNOTE-775 trial, chemotherapy demonstrated a limited durability of effect as only 4% of patients treated with chemotherapy were progression free at 12 months, and chemotherapy resulted in significant toxicity with 72.9% of patients exhibiting a Grade 3 or higher adverse event. Initial clinical results from the endometrial trial were presented in Context’s Q3 2022 earnings release and additional data are expected in mid-2023. Breast cancer (SMILE trial) : Metastatic breast cancer results in approximately 43,250 deaths per year in the United States. Primary treatment in the metastatic setting is antiestrogen plus CDK4/6 inhibitor combination therapy. CDK4/6 resistance is a clinical challenge due to the activation of resistance mechanisms that limit the utility of current standard-of-care treatments, including fulvestrant, after prior CDK4/6 inhibitor exposure. Initial data from a Phase 2 investigator-led clinical trial found that the combination of ONA-XR with fulvestrant in estrogen receptor-positive (ER+), HER2- locally advanced or metastatic breast cancer demonstrated a 4-month PFS rate of 44%, and favorable safety and tolerability in patients who had failed prior CDK4/6 inhibitor therapy in the metastatic setting. Preliminary results suggest that ONA-XR in combination with fulvestrant exhibits a favorable efficacy and tolerability profile relative to fulvestrant alone, which in a similar treatment setting to the SMILE trial, fulvestrant demonstrated a 1.9-month median PFS in the EMERALD Phase 3 trial 2 . The initial clinical results of the SMILE trial were presented in December 2022 at the San Antonio Breast Cancer Symposium and additional data are expected in Q4 2023. ELONA Phase 1b/2 breast cancer trial open and enrolled first patient: In January 2023, Context enrolled the first patient in the ELONA study, an open-label, Phase 1b/2 breast cancer clinical trial being conducted in partnership with The Menarini Group ("Menarini”). The ELONA study is designed to explore the efficacy of ONA-XR in combination with elacestrant, Menarini’s selective estrogen receptor degrader, in patients with locally advanced or metastatic breast cancer who have received prior treatment with a CDK4/6 inhibitor. In Menarini’s recently completed EMERALD Phase 3 trial, elacestrant demonstrated a 0.9-month PFS improvement versus the standard-of-care fulvestrant (2.8 vs 1.9 months) in a similar treatment population and as a result may become the standard-of-care antiestrogen treatment2. Compared to elacestrant alone, Context believes that the combination of ONA-XR plus elacestrant may more completely inhibit progesterone and estrogen hormone signaling that is required for breast cancer growth and metastasis. Such a combination would potentially improve outcomes in patients without adding significant toxicity. Story continues Cash Guidance The Company had cash and cash equivalents of $39.4 million as of September 30, 2022. The Company expects its current level of cash and cash equivalents will enable the Company to fund its operations into Q1 2024. About Context Therapeutics® Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for solid tumors, with a primary focus on female cancers. The Company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development. Context is also developing onapristone extended release (ONA-XR), a novel, first-in-class potent and selective progesterone receptor antagonist, currently in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancers. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on Twitter and LinkedIn. References [1] Makker V, et al.; KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022 Feb 3;386(5):437-448. [2] Bidard FC, et al; EMERALD Investigators. Elacestrant Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. Forward-looking Statements This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the expectation to provide a clinical data update from the OATH trial in mid-2023, as well as a Phase 2 data update from the SMILE trial and Phase 1b data for the ELONA trial in the fourth quarter of 2023, (ii) the expectation to have an IND submission for CTIM-76 in the first quarter of 2024, (iii) the selectivity, potency, and safety profile of CTIM-76, (iv) the timing, enrollment and results of our clinical trials, (v) the potential benefits and side effect profile of our product candidates, (vi) the likelihood data will support future development, and (vii) the likelihood of obtaining regulatory approval of our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Media Contact: Gina Cestari 6 Degrees 917-797-7904 gcestari@6degreespr.com Investor Relations Contact: Laine Yonker Edison Group lyonker@edisongroup.com

NEWS_540

Looking at Century Casinos, Inc.'s (NASDAQ:CNTY ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing. View our latest analysis for Century Casinos Century Casinos Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Chairman & Co-CEO Erwin Haitzmann for US$84k worth of shares, at about US$11.24 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$7.77). It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Erwin Haitzmann was the only individual insider to buy shares in the last twelve months. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying. Insider Ownership Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Century Casinos insiders own 9.5% of the company, worth about US$22m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. Story continues So What Do The Century Casinos Insider Transactions Indicate? The fact that there have been no Century Casinos insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. Insiders do have a stake in Century Casinos and their transactions don't cause us concern. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Century Casinos. Case in point: We've spotted 2 warning signs for Century Casinos you should be aware of, and 1 of these is potentially serious. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_541

PITTSBURGH, Jan. 5, 2023 /PRNewswire/ -- CNX Resources Corp. (NYSE: CNX) will announce its financial results for Q4 2022 at 6:45 a.m. Eastern Time on Thursday, January 26. At that time, CNX will issue a brief press release containing a link to presentation materials providing a Q4 2022 update, which will be available on CNX's Investor Relations website. This release will be followed by a conference call and webcast. Conference Call Information CNX Resources (NYSE: CNX) 10:00 a.m. ET: Thursday, January 26 Dial-In: 855-656-0928 (domestic) 412-902-4112 (international) Reference "CNX Resources Call" Webcast: investors.cnx.com A replay of the conference call and webcast will be maintained on the Investor Relations page on CNX's website. About CNX Resources CNX Resources Corporation (NYSE: CNX) is unique. We are a premier, low carbon intensive natural gas development, production, midstream, and technology company centered in Appalachia, one of the most energy abundant regions in the world. With the benefit of a 158-year regional legacy, substantial asset base, leading core operational competencies, technology development and innovation, and astute capital allocation methodologies, we responsibly develop our resources and deploy free cash flow to create long-term per share value for our shareholders, employees, and the communities where we operate. As of December 31, 2021, CNX had 9.63 trillion cubic feet equivalent of proved natural gas reserves. The company is a member of the Standard & Poor's Midcap 400 Index. Additional information is available at www.cnx.com. CNX Resources Corporation logo (PRNewsfoto/CNX Resources Corporation,CNX...) Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cnx-resources-corporation-announces-fourth-quarter-2022-financial-results-and-conference-call-schedule-301713472.html SOURCE CNX Resources Corporation

NEWS_542

CNX Resources Corporation (NYSE:CNX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. CNX Resources Corporation, an independent natural gas and midstream company, acquires, explores for, develops, and produces natural gas properties in the Appalachian Basin. The company’s loss has recently broadened since it announced a US$499m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$686m, moving it further away from breakeven. The most pressing concern for investors is CNX Resources' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company. Check out our latest analysis for CNX Resources Consensus from 5 of the American Oil and Gas analysts is that CNX Resources is on the verge of breakeven. They anticipate the company to incur a final loss in 2022, before generating positive profits of US$502m in 2023. So, the company is predicted to breakeven approximately a year from now or less! How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2023? Working backwards from analyst estimates, it turns out that they expect the company to grow 138% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. Underlying developments driving CNX Resources' growth isn’t the focus of this broad overview, but, take into account that typically an energy business has lumpy cash flows which are contingent on the natural resource and stage at which the company is operating. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments. Before we wrap up, there’s one issue worth mentioning. CNX Resources currently has a debt-to-equity ratio of 114%. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, and the company has considerably exceeded this. A higher level of debt requires more stringent capital management which increases the risk around investing in the loss-making company. Story continues Next Steps: There are key fundamentals of CNX Resources which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at CNX Resources, take a look at CNX Resources' company page on Simply Wall St. We've also compiled a list of key aspects you should look at: Valuation: What is CNX Resources worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether CNX Resources is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CNX Resources’s board and the CEO’s background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_543

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large. In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment. One stock to keep an eye on is American Airlines (AAL). AAL is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock is trading with P/E ratio of 8.82 right now. For comparison, its industry sports an average P/E of 12.59. Over the past year, AAL's Forward P/E has been as high as 9,493.45 and as low as -3,032.07, with a median of 11.71. Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. AAL has a P/S ratio of 0.23. This compares to its industry's average P/S of 0.52. Finally, investors will want to recognize that AAL has a P/CF ratio of 16.01. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. AAL's P/CF compares to its industry's average P/CF of 24.30. Over the past year, AAL's P/CF has been as high as 35.74 and as low as -305.42, with a median of 14.26. Story continues Another great Transportation - Airline stock you could consider is United Airlines (UAL), which is a # 2 (Buy) stock with a Value Score of A. Furthermore, United Airlines holds a P/B ratio of 3.23 and its industry's price-to-book ratio is 4.81. UAL's P/B has been as high as 4.68, as low as 2.01, with a median of 3 over the past 12 months. These are only a few of the key metrics included in American Airlines and United Airlines strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, AAL and UAL look like an impressive value stock at the moment. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report American Airlines Group Inc. (AAL) : Free Stock Analysis Report United Airlines Holdings Inc (UAL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_544

Shares of DuPont de Nemours Inc. DD, +1.80% rallied 1.80% to $75.30 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. DuPont de Nemours Inc. closed $8.78 below its 52-week high ($84.08), which the company achieved on February 18th. The stock outperformed some of its competitors Monday, as Linde PLC LIN, -0.65% fell 0.65% to $326.49. Trading volume (2.1 M) remained 846,811 below its 50-day average volume of 3.0 M.

NEWS_545

Shares of Deere & Co. DE, -0.31% dropped 0.31% to $409.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. Deere & Co. closed $39.06 short of its 52-week high ($448.40), which the company achieved on November 23rd. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Caterpillar Inc. CAT, +1.20% rose 1.20% to $252.70, CNH Industrial N.V. CNHI, +0.59% rose 0.59% to $17.12, and Toro Co. TTC, -0.71% fell 0.71% to $108.70. Trading volume (1.4 M) remained 161,322 below its 50-day average volume of 1.5 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_546

Shares of Discover Financial Services DFS, +3.91% rallied 3.91% to $110.29 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Discover Financial Services closed $18.83 below its 52-week high ($129.12), which the company achieved on February 15th. The stock outperformed some of its competitors Monday, as Apple Inc. AAPL, +2.35% rose 2.35% to $141.11, JPMorgan Chase & Co. JPM, +1.62% rose 1.62% to $137.27, and Visa Inc. Cl A V, -0.06% fell 0.06% to $224.18. Trading volume (3.6 M) eclipsed its 50-day average volume of 2.2 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_547

Shares of UDR Inc. UDR, -0.13% sank 0.13% to $39.93 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. UDR Inc. closed $20.08 below its 52-week high ($60.01), which the company reached on April 21st. The stock underperformed when compared to some of its competitors Monday, as Avalonbay Communities Inc. AVB, +0.01% rose 0.01% to $170.36, Equity Residential EQR, +0.44% rose 0.44% to $61.60, and Mid-America Apartment Communities Inc. MAA, +1.13% rose 1.13% to $157.22. Trading volume (1.5 M) remained 800,510 below its 50-day average volume of 2.3 M.

NEWS_548

Investors continue to navigate their way through earnings season, undoubtedly one of the most critical periods of the entire year for stocks. We’ve received a handful of quarterly results so far, including those from Goldman Sachs GS, Bank of America BAC, and Netflix NFLX, among others. This week, several financial companies report their results, including American Express AXP, on Friday, January 27th, before the market open. Below is a chart illustrating the stock’s performance over the last year, with the S&P 500 blended in as a benchmark. Zacks Investment Research Image Source: Zacks Investment Research How does the company stack up heading into the release? Fortunately, we can use quarterly results from Discover Financial Services DFS to help provide an idea. Discover Financial Services Q4 Discover posted better-than-expected quarterly results, exceeding the Zacks Consensus EPS Estimate of $3.58 by more than 5% and reflecting year-over-year growth of 4%. The company generated $3.7 billion in revenue throughout the quarter, edging out our $3.6 billion estimate by roughly 2% and growing 28% Y/Y. Total loans ended the quarter at $112.1 billion, climbing 20% year-over-year. In addition, net interest income grew 24% year-over-year thanks to higher average receivables and net interest margin expansion. Roger Hochschild, CEO, said, “Our outstanding results in 2022 were driven by record loan growth and margin expansion, factors that should sustain strong revenue growth into next year." Now, let’s take a look at American Express. American Express Over the last several months, four analysts have lowered their earnings outlook for the quarter, with the company currently carrying a Zacks Rank #4 (Sell). The Zacks Consensus EPS Estimate of $2.18 indicates zero change within the bottom line year-over-year. Zacks Investment Research Image Source: Zacks Investment Research However, the company’s top line is in better shape, with the $14.3 billion sales estimate indicating a change of 17% year-over-year. Below is a chart illustrating the company's revenue on a quarterly basis. Story continues Zacks Investment Research Image Source: Zacks Investment Research In addition, the Zacks Consensus Estimate for AXP’s net interest income presently stands at $2.7 billion, indicating a change of roughly 28% year-over-year and a 4.7% sequential climb. Regarding valuation, AXP shares currently trade at a 14.3X forward earnings multiple, below the 15.3X five-year median and marginally above the Zacks Finance sector average. Zacks Investment Research Image Source: Zacks Investment Research Further, the company’s price to book currently works out to be 4.7X, above the 4.5X five-year median and the Zacks Finance sector average. Zacks Investment Research Image Source: Zacks Investment Research AXP carries a Style Score of “B” for Value. Putting Everything Together With earnings season in full swing, investors are more than ready for companies to finally unveil what’s transpired behind closed doors. That’s precisely what we’ll receive from American Express AXP later this week on Friday, January 27th. Currently, estimates indicate zero change in earnings year-over-year but a solid uptick in quarterly revenue. In addition, the company’s net interest income is forecasted to grow at a solid pace, precisely what we saw from Discover Financial Services DFS in its quarterly release. Heading into the print, American Express carries a Zacks Rank #4 (Sell) with an Earnings ESP Score of -4.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Bank of America Corporation (BAC) : Free Stock Analysis Report Discover Financial Services (DFS) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report American Express Company (AXP) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_549

Analyst Report: Dollar General Corporation A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.

NEWS_550

Shares of Dollar General Corp. DG, +0.20% inched 0.20% higher to $231.07 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Dollar General Corp. closed $31.14 below its 52-week high ($262.21), which the company achieved on April 21st. The stock underperformed when compared to some of its competitors Monday, as Amazon.com Inc. AMZN, +0.28% rose 0.28% to $97.52, Walmart Inc. WMT, +1.49% rose 1.49% to $142.64, and Costco Wholesale Corp. COST, +2.60% rose 2.60% to $492.61. Trading volume (1.5 M) remained 585,200 below its 50-day average volume of 2.1 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_551

Dollar General (DG) closed the most recent trading day at $231.07, moving +0.2% from the previous trading session. This change lagged the S&P 500's 1.19% gain on the day. At the same time, the Dow added 0.76%, and the tech-heavy Nasdaq gained 0.29%. Prior to today's trading, shares of the discount retailer had lost 6.84% over the past month. This has lagged the Retail-Wholesale sector's gain of 8.04% and the S&P 500's gain of 4.06% in that time. Wall Street will be looking for positivity from Dollar General as it approaches its next earnings report date. On that day, Dollar General is projected to report earnings of $3.24 per share, which would represent year-over-year growth of 26.07%. Meanwhile, our latest consensus estimate is calling for revenue of $10.32 billion, up 19.26% from the prior-year quarter. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $10.94 per share and revenue of $37.96 billion. These totals would mark changes of +7.57% and +10.93%, respectively, from last year. Any recent changes to analyst estimates for Dollar General should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.03% lower. Dollar General currently has a Zacks Rank of #4 (Sell). Story continues Investors should also note Dollar General's current valuation metrics, including its Forward P/E ratio of 21.08. Its industry sports an average Forward P/E of 26.93, so we one might conclude that Dollar General is trading at a discount comparatively. It is also worth noting that DG currently has a PEG ratio of 1.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Retail - Discount Stores industry currently had an average PEG ratio of 2.5 as of yesterday's close. The Retail - Discount Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dollar General Corporation (DG) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_552

Shares of Quest Diagnostics Inc. DGX, +1.09% advanced 1.09% to $147.01 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's third consecutive day of gains. Quest Diagnostics Inc. closed $11.33 short of its 52-week high ($158.34), which the company achieved on December 29th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as UnitedHealth Group Inc. UNH, -0.19% fell 0.19% to $485.81, IQVIA Holdings Inc. IQV, +2.30% rose 2.30% to $228.75, and Centene Corp. CNC, -0.47% fell 0.47% to $75.79. Trading volume (1.0 M) remained 90,398 below its 50-day average volume of 1.1 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_553

Shares of Universal Health Services Inc. Cl B UHS, -0.71% shed 0.71% to $148.41 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. The stock's fall snapped a two-day winning streak. Universal Health Services Inc. Cl B closed $9.87 below its 52-week high ($158.28), which the company reached on April 21st. The stock underperformed when compared to some of its competitors Monday, as Select Medical Holdings Corp. SEM, +0.53% rose 0.53% to $28.71, Community Health Systems Inc. CYH, +0.85% rose 0.85% to $4.75, and Pediatrix Medical Group Inc. MD, +0.53% rose 0.53% to $15.28. Trading volume (494,756) remained 222,919 below its 50-day average volume of 717,675. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_554

Quest Launches the First Annual "Know Your Health" Survey to Inspire Americans to Take Control of Their Well-being in 2023 SECAUCUS, N.J., Jan. 23, 2023 /PRNewswire/ -- The consumer-initiated testing business from the leader in diagnostic testing, Quest Diagnostics (NYSE: DGX), today revealed the results of the first annual "Know Your Health" survey. Aimed to empower Americans to take ownership of their health in the new year, the survey highlights how the U.S. adult population prioritizes their health, where they go for medical advice, and how proactive they are with staying on top of their overall well-being. With an influx of conflicting health and wellness information, where opinion is often presented as fact, lab work offers an individualized look at your wellness and is the first step to a healthier you. Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated) The Information We Know (or Don't) From pop culture to our finances, Americans are fixated on being on top of this information all day, every day. But could this abundance of information keep us from prioritizing our health? Quest commissioned a survey conducted online by The Harris Poll among over 2,000 U.S. adults, which reveals that more Americans know their horoscope sign (66%) and credit score (58%) than their blood type (51%) or cholesterol level (20%). This becomes even more apparent when broken down by generation, with less than half (47%) of Millennials (ages 26-41) and only one-third (32%) of Gen Z (ages 18-25) reporting being aware of their blood type. "For example, having high cholesterol levels may not have any symptoms, but it increases your risk for heart disease and stroke," said Nick Bellos, MD, National Medical Director Extended Care Services, Quest Diagnostics. "Knowing where you stand through diagnostic testing, whether it be your cholesterol level or other markers, will help you manage your health today to hopefully stave off disease and costly treatments in the future." Sources of Information When seeking out health information, Americans are inundated with noise which can lead to challenges in knowing what advice or data is helpful or accurate. While the majority of Americans (63%) get health advice from healthcare professionals (HCPs), roughly 2 in 5 of Gen Z (44%) get health advice from an HCP, while more than half (52%) utilize Internet searches. Nearly 1 in 4 Americans (22%) get health advice from social media influencers, highest among Gen Z (40%) and Millennials (39%) vs. just 18% of Gen X (ages 42-57) and 3% of Boomers (ages 58-76). Story continues "Unfortunately, there's no one-size-fits-all diet or wellness routine, as everyone's body is different," said Dr. Bellos. "The single best way to assess what's truly going on inside your body is through a simple, laboratory test that offers the essential knowledge and actionable diagnostic insights." Self-Testing / Self Care As a result of the COVID-19 pandemic, consumers have become more open to re-imagining their healthcare. For instance, while over half of Americans (57%) say they have procrastinated scheduling a routine check-up, the majority of Americans (69%) are comfortable with telehealth visits. Americans are getting comfortable with lab testing without first visiting a doctor. The prevalence of COVID-19 brought self-initiated testing to the forefront, with 4 in 5 (81%) claiming they're comfortable using at-home covid tests. As awareness grows, Americans may become more aware of the possibility of purchasing other lab tests (thyroid, cholesterol, food allergies, etc.) without a prior in-person doctor's visit – currently, just over one-third (37%) know it's possible. "Now more than ever, consumers are interested in convenient and individualized healthcare that puts the power back in their hands. Being proactive in seeking out personal diagnostics offers consumers the capacity to help them avoid potential health complications in the future and live a healthier life," said Dr. Bellos. Quest's consumer-initiated test service is designed to empower people with the information and data they need about their health, with access to the same quality tests used by doctors and hospitals. With over 55 tests available, including a food allergy panel , complete blood count , comprehensive metabolic panel , and many more, consumers can conveniently shop online and choose their own lab tests, schedule appointments for tests, and access results securely from a phone or computer. For more information, please visit questhealth.com or follow @testwithquest on Instagram , Facebook , and Twitter . About Our Commitment to Consumer Empowered Health Quest has long been a leader in empowering consumers by making affordable, high-quality, trusted healthcare as easy as possible. With innovative tools, we give consumers more control over their own healthcare journeys and meet them where they are, supporting both consumers and their care team. Our online shop at questhealth.com has made it fast, confidential, and convenient for consumers to access dozens of tests from general health profiles to tests for conditions ranging from heart health to sexually transmitted diseases. PWNHealth and its affiliates will review the patient's purchase to ensure it is medically appropriate before submitting a test order for processing. PWN will also review the test results and contact patients directly if the results require prompt attention. Consumers can review, print, and share results with their personal physicians, or PWNHealth, and its affiliates are available to discuss. We were among the first diagnostic testing providers to offer free access to test results online. Our mobile app and patient portal, MyQuest , is accessed by millions of people who view and track their test results and other health data. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com . Survey Methodology This survey was conducted online within the United States by The Harris Poll on behalf of Quest from December 19-21, 2022, among 2,085 adults ages 18+. The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data is accurate to within + 2.8 percentage points using a 95% confidence level. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact Gina DeCandia at mediacontact@questdiagnostics.com. Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/more-americans-know-their-horoscope-sign-than-their-blood-type-survey-reveals-301727634.html SOURCE Quest Diagnostics

NEWS_555

NORTHAMPTON, MA / ACCESSWIRE / January 23, 2023 / Quest Diagnostics Quest Diagnostics , Monday, January 23, 2023, Press release picture Quest mobile unit supports a community COVID-19 testing event in Newark, NJ. "Together, we will leverage our insights, our knowledge, and our collective commitment to help ensure everyone- regardless of income, ethnicity, geography, or demographics- has equal opportunity for better health." Mandell Jackson, Vice President and General Manager, Q4HE The COVID-19 pandemic has had a disproportionate impact on those from certain racial and ethnic groups. This has served to further expose the enduring healthcare disparities that existed long before the pandemic. We continue to engage in meaningful cooperative initiatives to face and help resolve the root causes of the systemic inequities fueling this crisis and work towards impactful solutions. Launched in 2020, Quest for Health Equity, or Q4HE, is an initiative established by Quest Diagnostics and the Quest Diagnostics Foundation focused on taking action to address health disparities across the US. Through education, engagement, empowerment, and access, Q4HE aims to provide access to essential resources for underserved communities. Q4HE strategies COVID-19 testing, vaccinations, and treatment Funding programs that address the root causes of health inequities Partnering with organizations focused on creating lasting change for persons in groups that have been historically marginalized, initiating education and outreach efforts, and otherwise enabling better health outcomes With strong support from Quest Diagnostics leadership, Q4HE draws upon leadership and expertise from across the organization. Because Quest understands that achieving health equity is a marathon, not a sprint, Q4HE is supporting multiple national, regional, and local programs directed at the critical challenges faced by traditionally underserved communities. Following are a few snapshots of Q4HE's many efforts. Read more View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com. Story continues Contact Info: Spokesperson: Quest Diagnostics Website: https://www.3blmedia.com/profiles/quest-diagnostics Email: info@3blmedia.com SOURCE: Quest Diagnostics View source version on accesswire.com: https://www.accesswire.com/736322/Advancing-Healthcare-Equity-in-Underserved-Communities

NEWS_556

Shares of D.R. Horton Inc. DHI, +1.27% rallied 1.27% to $95.68 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. D.R. Horton Inc. closed $1.64 below its 52-week high ($97.32), which the company achieved on January 18th. The stock outperformed some of its competitors Monday, as Lennar Corp. Cl A LEN, +0.87% rose 0.87% to $97.53, Lennar Corp. Cl B LEN.B, +0.87% rose 0.87% to $81.30, and Invitation Homes Inc. INVH, -0.22% fell 0.22% to $31.46. Trading volume (3.1 M) eclipsed its 50-day average volume of 2.8 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_557

Investors with an interest in Diversified Operations stocks have likely encountered both Hitachi Ltd. (HTHIY) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits. Currently, Hitachi Ltd. has a Zacks Rank of #1 (Strong Buy), while Danaher has a Zacks Rank of #4 (Sell). Investors should feel comfortable knowing that HTHIY likely has seen a stronger improvement to its earnings outlook than DHR has recently. But this is only part of the picture for value investors. Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. HTHIY currently has a forward P/E ratio of 11.36, while DHR has a forward P/E of 26.47. We also note that HTHIY has a PEG ratio of 1.90. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DHR currently has a PEG ratio of 2.21. Another notable valuation metric for HTHIY is its P/B ratio of 1.33. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, DHR has a P/B of 4.41. These metrics, and several others, help HTHIY earn a Value grade of B, while DHR has been given a Value grade of F. Story continues HTHIY has seen stronger estimate revision activity and sports more attractive valuation metrics than DHR, so it seems like value investors will conclude that HTHIY is the superior option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hitachi Ltd. (HTHIY) : Free Stock Analysis Report Danaher Corporation (DHR) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_558

Shares of Danaher Corp. DHR, +0.95% inched 0.95% higher to $277.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's third consecutive day of gains. Danaher Corp. closed $26.82 below its 52-week high ($303.82), which the company achieved on August 15th. Trading volume (2.1 M) remained 321,155 below its 50-day average volume of 2.4 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_559

Shares of Ulta Beauty Inc. ULTA, +1.88% rallied 1.88% to $500.47 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Ulta Beauty Inc. closed $0.97 below its 52-week high ($501.44), which the company achieved on January 18th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Target Corp. TGT, +1.49% rose 1.49% to $164.63 and Macy's Inc. M, +2.81% rose 2.81% to $23.40. Trading volume (417,886) remained 242,699 below its 50-day average volume of 660,585. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_560

Walt Disney’s Star Wars-themed Orlando hotel dubbed the Galactic Starcruiser is turning into the latest potential headache for Bob Iger. The Mouse House CEO received a fresh two-year mandate to return to Disney and work his magic after the board unceremoniously fired successor Bob Chapek in late November in response to growing losses at its streaming business. The veteran CEO promptly got to work unraveling one of the core strategic decisions taken by Chapek and sacked his top lieutenant, Kareem Daniel. But now Iger faces problems at one of Disney’s flagship attractions, barely a year after it opened. Struggling to attract visitors to its pricey $5,000-per-package Starcruiser hotel, Disney began last week offering rare discounts of up to $700 off the two-day stay if customers book accommodations at other participating hotels in a promotional deal that lasts all the way through the end of September. While it's not unusual for hotels—even those run by Disney—to offer discounts of anywhere between 10%-25%, the Star Wars-themed faux space travel package is a deal executives have said would justify its premium price through the immersive experience. Moreover, the Galactic Starcruiser is a brand new offering from Disney, so it's rare that it would already be subject to its first promotional discount. Originally offered exclusively to Disney Vacation Club members, this 30% special offer has now been expanded to the general public in another sign that it's not living up to expectations. “Guests have been clamoring for these changes," wrote Rick Munarriz, a Florida-based stock analyst focusing on Disney for Motley Fool, on Thursday, "but it's also a way to woo potentially disgruntled fans back at a time of weaker demand." Disney did not respond to an inquiry by Fortune for comment. Galactic Starcruiser's journey so far Opening its doors in Orlando last March, the timing of the Galactic Starcruiser's arrival at Walt Disney World couldn’t have been much better. Story continues Flush with stimulus checks, brimming with optimism after a post-pandemic economic boom and desperate to finally enjoy an actual vacation for once, guests descended by the masses on Disney’s theme parks. In its fiscal year 2022 that ended October 1st, annual operating income for the entertainment giant's tourism segment catapulted to $7.9 billion from just $471 million in the previous period. By comparison its media activities, the other far larger arm that generates about twice as much revenue, saw a 42% drop in profit due mainly to its heavy investments in streaming to better compete with Netflix. Perhaps that outsized earnings gain at its parks business led executives at Disney to believe they had a sure-fire hit on their hands with the Galactic Starcruiser hotel. It is billed as a two-night immersive experience where guests become the hero of their own Star Wars adventure aboard the Halcyon. The stay features its own storylines, lightsaber training, gourmet eating at the fictional ship’s Crown of Corellia dining area, and a spaceport day on the fictional planet of Batuu at Disney’s popular Galaxy’s Edge attraction. Unfortunately, the price of a cabin on the Starcruiser was also out of this world: a packaged deal for two adults and one child started at a combined fee of $5,299 for two nights. Despite the expensive cost, the then-CEO of Disney believed it to be a compelling deal. Characterizing interest in the experience as “phenomenal” two months after it opened its doors, Bob Chapek said the first customer ratings were “incredibly high” during an investor update. “Demand is strong and we expect 100% utilization through the end of Q3,” he said last May. By that point, however, the Federal Reserve found itself in full blown inflation-fighting mode and financial markets were starting to take it in the knee as a result of repeated interest rate hikes. Brokerage accounts once stuffed full of Tesla shares and Bitcoin cryptocurrency now shriveled in value, leaving people feeling poorer. The good news for investors subsequently appears to have dried up there. Never again did Chapek plug the Star Wars-themed hotel or provide data on demand during a quarterly earnings call. Any search in Disney’s 112-page long annual 10-K filing with the SEC dated late November comes up blank. Critical misfires It also may be indicative of broader problems stemming from Disney’s stewardship over the once beloved science-fiction franchise. While the wildly successful Mandalorian, a show conceived by Iron Man director Jon Favreau, helped launch Disney’s streaming service in 2019, attempts to expand the rich universe have misfired lately. Series like Obi-Wan Kenobi disappointed despite the return of star Ewan McGregor, for example. Only Andor, the Rogue One spin-off series based around Rebellion spy Cassian Andor, has been a clear critical hit recently. Consequently rumors emerged that Lucasfilm President Kathleen Kennedy, a divisive figure among fans for entrusting J.J. Abrams with the third trilogy, may lose her job once the Indiana Jones and the Dial of Destiny premieres in theaters this summer. Fortunately, interest in the Star Wars franchise may return with the third season of The Mandalorian, debuting in March. The trailer drew in a record 83 million-plus views in the first 24 hours, according to the Hollywood Reporter. Disney is set to report Q1 results on February 8th, with many analysts keen to see whether the company narrowed quarterly losses that had ballooned by 50% to nearly $1.5 billion. This story was originally featured on Fortune.com More from Fortune: Air India slammed for ‘systemic failure’ after unruly male passenger flying business class urinated on a woman traveling from New York Meghan Markle’s real sin that the British public can’t forgive–and Americans can’t understand ‘It just doesn’t work.’ The world’s best restaurant is shutting down as its owner calls the modern fine dining model ‘unsustainable’ Bob Iger just put his foot down and told Disney employees to come back into the office

NEWS_561

Apple in talks with Disney, others on VR content for new headset - Bloomberg News (Reuters) - Apple Inc was in talks with about half a dozen media partners including Walt Disney Co to develop virtual reality (VR) content for its mixed reality headset, Bloomberg News reported on Monday. Developed with Sony Group Corp, the headset will have two ultra-high-resolution displays to handle the VR aspects and a collection of external cameras to enable an augmented reality "pass-through mode", the report said. It added that the tech giant was working to update its own Apple TV+ material to work with the headset. Disney, Apple and Sony did not immediately respond to Reuters requests for comment. Earlier this month, Bloomberg reported that Apple was planning to unveil its first mixed reality (MR) headset this year. MR is one of three types of extended reality technologies often associated with the metaverse. An MR headset could allow the wearer to use a real world object to trigger a virtual world reaction. The iPhone maker's MR headset is set to launch in this year's spring event and will cost around $3,000, according to the report. That would be twice as much as Meta Platforms Inc's Quest Pro virtual and MR headset, which was launched late last year for $1,500. (Reporting by Tiyashi Datta in Bengaluru; Editing by Devika Syamnath)

NEWS_562

Good morning, “Companies have to think very carefully and very strategically about how they approach pricing strategy,” EY Parthenon chief economist Gregory Daco tells me. “We're no longer in the 2021 or 2022 environment where demand was quite robust and companies were being rewarded for exercising pricing power because everybody was doing so.” Procter & Gamble (P&G), the maker of consumer goods like Tide, Pampers, and Charmin, has a strategy to offset higher material costs and supplier inflation by continuing price hikes and showing product innovation. Prices across categories increased by 10%, but sales volume decreased by 6% from the year prior, according to the latest earnings report for the period ending Dec. 31. More price increases will go into effect in February, Andre Schulten, CFO at P&G, said on the Jan. 19 earnings call. The drop in sales volume was consumption-driven, and the other half was due to inventory reductions in China and Russia, Schulten said. P&G net sales for the quarter ($20.77 billion) were down 1%, but surpassing analysts’ average projections of $20.73 billion. The higher pricing resulted in organic revenues increasing by 5%. Regarding product innovation, P&G chairman, president, and CEO Jon Moeller pointed to Dawn Powerwash dish spray. The product creates suds inside the spray chamber, letting you apply those directly to the dishes. Compared to non-ultra Dawn, the company claims Powerwash is five times faster at cutting through grease. Powerwash hit the market in January 2020. It was at a premium price, Moeller said on the earnings call. “The brand has grown at 50% since that introduction, and Dawn has driven 90% of category growth in that situation,” he said. “We've got a lot of innovation coming.” Meanwhile, in 2022, Chipotle Mexican Grill, Inc. (NYSE: CMG) increased menu prices at least three times. That’s due to factors such as inflation in ingredient costs, wage inflation, and energy prices, CFO Jack Hartung told me late last year. "When we look at our menu prices compared to competitors, we’re still a terrific value,” Hartung said. “Our food cost and our people cost are by far the largest items on the P&L," he said. "We don’t want to cut back on our food. We’ve never tried to reduce the quality of our fresh ingredients. We want to invest more in food and our people.” Story continues Chipotle's total revenue increased 13.7% to $2.2 billion in Q3 2022. In-restaurant sales rose 22.1% year-over-year. However, that’s less than the second quarter, when in-restaurant sales increased 35.9% compared to the year prior. During our talk, Hartung told me that in Q4, prices could increase 15% year over year until it drops down to 11% in the first quarter of 2023. Chipotle's Q4 earnings are scheduled to be released on Feb. 7. On Oct. 25 (when Q3 earnings were announced), CMG closed at $1,584.02. It closed at $1,555.19 on Jan. 20. Then there's Disney. Under returning CEO Robert Iger, The Walt Disney Company is trying to get back into the good graces of loyal customers by reversing some park-related fees from former CEO Bob Chapek's era. However, they're not exactly lowering ticket prices across the board. Disney’s parks chief, Josh D’Amaro, said in a blog post on Jan. 10 that customers of Disneyland resort in Anaheim will have greater access to the lowest priced tickets—"nearly two months worth of $104 park ticket dates." After a price increase in October, a one-day Disneyland ticket now ranges from $104 to $179, based on the day. Other perks include, beginning on Feb. 4, customers can access photos taken at rides for free instead of paying for a photo pass. At Disney World Resort in Orlando, guests with annual passes are now able to enter the parks after 2 p.m. without first securing a reservation. (With the exception of weekends at the Magic Kingdom park.) Overnight self-parking will once again be complimentary to guests staying at Disney resort hotels. Guests buying the Disney Genie+ service will also get digital downloads of their attraction photos. “While this doesn’t address everyone’s feedback, these changes will increase flexibility and add value to our guests’ experience,” D’Amaro said in the blog post. Disney's latest earnings report is scheduled for Feb. 8. In order to create the most effective price strategy, “every company has to evaluate its market position, brand position, and client base," Daco says. “There's no one formula for every company," he says. *Quick note: I have a question for finance chiefs: What is the most important thing you did before landing your first CFO position? (For example, was it networking, or P&L management, or something else?) What made you ready to take on a CFO position? Share your experience and insights with the next generation of CFOs for an upcoming column. Send me an email! See you tomorrow. Sheryl Estrada sheryl.estrada@fortune.com This story was originally featured on Fortune.com More from Fortune: Air India slammed for ‘systemic failure’ after unruly male passenger flying business class urinated on a woman traveling from New York Meghan Markle’s real sin that the British public can’t forgive–and Americans can’t understand ‘It just doesn’t work.’ The world’s best restaurant is shutting down as its owner calls the modern fine dining model ‘unsustainable’ Bob Iger just put his foot down and told Disney employees to come back into the office

NEWS_563

Shares of Walt Disney Co. DIS, +2.14% rose 2.14% to $105.69 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's third consecutive day of gains. Walt Disney Co. closed $51.81 below its 52-week high ($157.50), which the company reached on February 10th. The stock underperformed when compared to some of its competitors Monday, as Apple Inc. AAPL, +2.35% rose 2.35% to $141.11, Netflix Inc. NFLX, +4.36% rose 4.36% to $357.42, and Comcast Corp. Cl A CMCSA, +2.26% rose 2.26% to $40.26. Trading volume (11.3 M) remained 5.6 million below its 50-day average volume of 16.9 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_564

Shares of DISH Network Corp. Cl A DISH, +4.75% rose 4.75% to $14.56 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. DISH Network Corp. Cl A closed $19.18 below its 52-week high ($33.74), which the company reached on April 18th. The stock outperformed some of its competitors Monday, as Amazon.com Inc. AMZN, +0.28% rose 0.28% to $97.52, Netflix Inc. NFLX, +4.36% rose 4.36% to $357.42, and Walt Disney Co. DIS, +2.14% rose 2.14% to $105.69. Trading volume (5.3 M) eclipsed its 50-day average volume of 4.4 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_565

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like UnitedHealth Group (NYSE:UNH). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. View our latest analysis for UnitedHealth Group How Fast Is UnitedHealth Group Growing? Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That makes EPS growth an attractive quality for any company. Over the last three years, UnitedHealth Group has grown EPS by 14% per year. That's a pretty good rate, if the company can sustain it. It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. It's noted that UnitedHealth Group's revenue from operations was lower than its revenue in the last twelve months, so that could distort our analysis of its margins. EBIT margins for UnitedHealth Group remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 13% to US$324b. That's progress. The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image. In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of UnitedHealth Group's forecast profits? Story continues Are UnitedHealth Group Insiders Aligned With All Shareholders? We would not expect to see insiders owning a large percentage of a US$455b company like UnitedHealth Group. But we do take comfort from the fact that they are investors in the company. Indeed, they have a considerable amount of wealth invested in it, currently valued at US$1.5b. This comes in at 0.3% of shares in the company, which is a fair amount of a business of this size. So despite their percentage holding being low, company management still have plenty of reasons to deliver the best outcomes for investors. Should You Add UnitedHealth Group To Your Watchlist? As previously touched on, UnitedHealth Group is a growing business, which is encouraging. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. The combination definitely favoured by investors so consider keeping the company on a watchlist. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for UnitedHealth Group that you should be aware of. Although UnitedHealth Group certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see insider buying, then this free list of growing companies that insiders are buying, could be exactly what you're looking for. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_566

Shares of UnitedHealth Group Inc. UNH, -0.19% slid 0.19% to $485.81 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. The stock's fall snapped a two-day winning streak. UnitedHealth Group Inc. closed $72.29 below its 52-week high ($558.10), which the company achieved on October 31st. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as CVS Health Corp. CVS, +0.23% rose 0.23% to $87.20, Elevance Health Inc. ELV, -0.32% fell 0.32% to $477.94, and Cigna Corp. CI, -0.06% fell 0.06% to $308.17. Trading volume (3.4 M) remained 60,433 below its 50-day average volume of 3.5 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_567

Shares of Union Pacific Corp. UNP, +0.70% inched 0.70% higher to $210.13 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Union Pacific Corp. closed $68.81 short of its 52-week high ($278.94), which the company reached on March 31st. Trading volume (3.2 M) eclipsed its 50-day average volume of 2.9 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_568

Shares of Digital Realty Trust Inc. DLR, +0.45% inched 0.45% higher to $107.22 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Digital Realty Trust Inc. closed $47.24 short of its 52-week high ($154.46), which the company reached on January 25th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Prologis Inc. PLD, +2.65% rose 2.65% to $126.07, Alexandria Real Estate Equities Inc. ARE, +1.27% rose 1.27% to $159.04, and Boston Properties Inc. BXP, -0.04% fell 0.04% to $71.17. Trading volume (1.2 M) remained 703,157 below its 50-day average volume of 1.9 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_569

jetcityimage / iStock.com Dollar Tree may be the place you only go for quick and affordable party or cleaning supplies, but you’d be amazed at the breadth of items the discount store offers each season. See: GOBankingRates’ Best Online Banks 2023 More: 3 Ways Smart People Save Money When Filing Their Taxes Related: 10 Best New Items Coming to Dollar Tree in 2023 While we’re in the middle of winter, it’s the perfect time to stock up on affordable items that can make the rest of your season cozier and tastier. Here are the best Dollar Tree items to buy now for winter. Kids Mittens When the cold weather rolls in, kids need cozy mittens to keep their little hands toasty. But if you have kids, you know there’s nothing harder to keep track of than a pair of anything. Don’t fret, these cute, patterned winter mittens from Dollar Tree only cost $1.25 per pair. So, it’s not too painful, or expensive, if your kiddo loses one. Storage Bins With winter often comes an entire wardrobe change, and unless you’re living in a mansion you probably don’t have the closet space to fit all four seasons worth of clothing. Fear not! You can put away your summer clothing in these handy, clear storage bins. You can also use them to put away summer gardening equipment, kids toys that won’t be in use for the season, or store dry goods and food in your garage so you can do less shopping in inclement weather. However, you use them, you can’t go wrong at $1.25 per bin. Take Our Poll: How Much of a Tax Refund Do You Expect in 2023? Oven Mitts Cooler weather often means a warmer kitchen, as it’s the perfect time to crank up the oven without worrying about overheating. Hot meals are the stuff of winter months, and if you’re a busy baker or cook, you probably could use a brand new pair of oven mitts. These cute pet-themed oven mitts are affordable and practical. Soup Mugs Cold weather and hot soup — they just go together. And the wonderful thing about soup is that there are endless possibilities. Story continues Whether you like to make thick stews, broths full of veggies and spices, or hearty minestrone and split pea, you’re going to need a sturdy soup container to serve it in. Dollar Tree offers big soup mugs with an easy-to-hold handle in three simple colors, sure to pair with any dishware you already have. Soup For every person who loves to bake, there’s another who doesn’t or can’t find the time. Dollar Tree has the solution for the latter with a variety of prepared soups in cans, such as Healthy Choice Chicken With Rice Soup, or Campbell’s Condensed Tomato Soup, both just $1.25 for a 15 oz can. Loaf Pans As we’ve made clear, winter and the holiday season is a major time for baking. ‘Tis the season for pumpkin bread, gingerbread, zucchini bread and more — so get as many pans as you need for just $1.25 each. Battery-Operated Candles Winter weather often means winter storms, and sometimes that includes power outages. You can stay prepared with these 4-inch, battery-operated ivory wax LED pillar candles. Or, create a gentle ambience for holiday events or just a calm night at home. Have a nice and safe winter, everyone! More From GOBankingRates This article originally appeared on GOBankingRates.com: 7 Best Winter Items To Buy at Dollar Tree Now

NEWS_570

Shares of Dollar Tree Inc. DLTR, +2.17% advanced 2.17% to $150.99 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Dollar Tree Inc. closed $26.20 below its 52-week high ($177.19), which the company reached on April 21st. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Amazon.com Inc. AMZN, +0.28% rose 0.28% to $97.52, Walmart Inc. WMT, +1.49% rose 1.49% to $142.64, and Costco Wholesale Corp. COST, +2.60% rose 2.60% to $492.61. Trading volume (2.8 M) eclipsed its 50-day average volume of 2.2 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_571

Shares of United Parcel Service Inc. Cl B UPS, +1.32% rallied 1.32% to $180.48 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. United Parcel Service Inc. Cl B closed $53.24 below its 52-week high ($233.72), which the company reached on February 1st. Trading volume (2.2 M) remained 807,880 below its 50-day average volume of 3.0 M.

NEWS_572

United Parcel Service (UPS) closed the most recent trading day at $180.48, moving +1.32% from the previous trading session. The stock outpaced the S&P 500's daily gain of 1.19%. At the same time, the Dow added 0.76%, and the tech-heavy Nasdaq gained 0.29%. Coming into today, shares of the package delivery service had gained 0.63% in the past month. In that same time, the Transportation sector gained 5.66%, while the S&P 500 gained 4.06%. United Parcel Service will be looking to display strength as it nears its next earnings release, which is expected to be January 31, 2023. The company is expected to report EPS of $3.58, down 0.28% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $28.09 billion, up 1.15% from the prior-year quarter. Investors might also notice recent changes to analyst estimates for United Parcel Service. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. United Parcel Service is currently a Zacks Rank #3 (Hold). Digging into valuation, United Parcel Service currently has a Forward P/E ratio of 14.65. For comparison, its industry has an average Forward P/E of 13.74, which means United Parcel Service is trading at a premium to the group. Investors should also note that UPS has a PEG ratio of 1.81 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Transportation - Air Freight and Cargo was holding an average PEG ratio of 1.81 at yesterday's closing price. Story continues The Transportation - Air Freight and Cargo industry is part of the Transportation sector. This industry currently has a Zacks Industry Rank of 92, which puts it in the top 37% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow UPS in the coming trading sessions, be sure to utilize Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_573

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of United Rentals, Inc. (NYSE:URI) as an investment opportunity by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. It may sound complicated, but actually it is quite simple! We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you. See our latest analysis for United Rentals Step By Step Through The Calculation We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 10-year free cash flow (FCF) estimate 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 Levered FCF ($, Millions) US$2.07b US$2.46b US$2.33b US$2.75b US$2.91b US$3.06b US$3.18b US$3.29b US$3.39b US$3.48b Growth Rate Estimate Source Analyst x6 Analyst x5 Analyst x2 Analyst x1 Est @ 6.13% Est @ 4.89% Est @ 4.02% Est @ 3.40% Est @ 2.98% Est @ 2.68% Present Value ($, Millions) Discounted @ 9.5% US$1.9k US$2.1k US$1.8k US$1.9k US$1.9k US$1.8k US$1.7k US$1.6k US$1.5k US$1.4k ("Est" = FCF growth rate estimated by Simply Wall St) Present Value of 10-year Cash Flow (PVCF) = US$17b Story continues The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.0%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 9.5%. Terminal Value (TV)= FCF 2032 × (1 + g) ÷ (r – g) = US$3.5b× (1 + 2.0%) ÷ (9.5%– 2.0%) = US$47b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$47b÷ ( 1 + 9.5%)10= US$19b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$36b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of US$384, the company appears a touch undervalued at a 27% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. dcf The Assumptions We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at United Rentals as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 9.5%, which is based on a levered beta of 1.251. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. SWOT Analysis for United Rentals Strength Earnings growth over the past year exceeded the industry. Debt is well covered by earnings and cashflows. Weakness No major weaknesses identified for URI. Opportunity Annual revenue is forecast to grow faster than the American market. Good value based on P/E ratio and estimated fair value. Significant insider buying over the past 3 months. Threat Annual earnings are forecast to grow slower than the American market. Next Steps: Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. What is the reason for the share price sitting below the intrinsic value? For United Rentals, there are three additional items you should further research: Risks: We feel that you should assess the 1 warning sign for United Rentals we've flagged before making an investment in the company. Management:Have insiders been ramping up their shares to take advantage of the market's sentiment for URI's future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NYSE every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_574

Shares of United Rentals Inc. URI, +2.18% rallied 2.18% to $392.03 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. United Rentals Inc. closed $2.37 below its 52-week high ($394.40), which the company reached on January 18th. The stock outperformed some of its competitors Monday, as Herc Holdings Inc. HRI, +1.88% rose 1.88% to $146.16. Trading volume (743,076) eclipsed its 50-day average volume of 656,646.

NEWS_575

Coming out of the pandemic, there were many newly found shortages. These shortages led to higher prices for consumers across the globe. It also made for some incredible years for several companies. Many were able to charge prices that they will never see again, with unbelievable margins as well. Moving forward, it has become tough to recognize which companies will be able to keep their margins high and keep the profits rolling in. One way to figure it out is by leaning on the Zacks Rank. Stocks in the good graces of our Zacks Rank have the strongest earnings trends, which are most likely to continue on in the future. One such stock is today’s Bull of the Day, United Rentals URI. United Rentals, Inc. is the largest equipment rental company in the world. It provides rental equipment for a diverse range of industries and uses, including construction, manufacturing, transportation, oil and gas, government, and disaster response. The company has an extensive inventory of equipment, including earthmoving equipment, aerial work platforms, power and HVAC equipment, pumps, tools, and more. United Rentals operates through a network of over 1,300 rental locations in North America and 11 other countries. Zacks Investment Research Image Source: Zacks Investment Research Over the last sixty days, five analysts have increased their earnings estimates for next year. That bullish behavior is the recent why the stock is currently a Zacks Rank #1 (Strong Buy). These revisions have also pushed up our Zacks Consensus Estimate for next year from $35.25 to $37.58. That now represents earnings growth of 15.5% for next year. Current year growth is even stronger, at 47.46%. The stock has had one of the strongest Price, Consensus and EPS Surprise Charts over the last few years. Earnings bottomed out into the depths of the COVID shutdown. Since then, earnings have consistently grown year-over-year. Not only have earnings been on the rise year-over-year, but estimates have ticked up nearly each and every month. Story continues Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Rentals, Inc. (URI) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_576

NORTHAMPTON, MA / ACCESSWIRE / January 23, 2023 / Originally published on U.S. Bank company blog With regions of California being impacted by a series of torrential rainstorms, U.S. Bank announced it will provide a $25,000 U.S. Bank Foundation contribution to the Northern California Coastal Region Red Cross in support of disaster relief efforts. U.S. Bank, Monday, January 23, 2023, Press release picture The U.S. Bank Foundation is a proud supporter of the American Red Cross Disaster Responder Program, contributing an annual $150,000 grant, and also provides about $500,000 in combined giving to the Red Cross each year through additional contributions, employee matching gifts and donations made by customers at U.S. Bank ATMs. As California braces for more storms, U.S. Bank continues to prepare, respond to and support impacted employees, customers and communities. Additionally, the U.S. Bank Disaster Relief Assistance page offers resources for dealing with natural disasters. Learn more about U.S. Bank here View additional multimedia and more ESG storytelling from U.S. Bank on 3blmedia.com. Contact Info: Spokesperson: U.S. Bank Website: https://www.3blmedia.com/profiles/us-bank Email: info@3blmedia.com SOURCE: U.S. Bank View source version on accesswire.com: https://www.accesswire.com/736259/Responding-to-Floods-in-California

NEWS_577

Shares of U.S. Bancorp USB, +2.60% advanced 2.60% to $47.67 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. U.S. Bancorp closed $12.83 below its 52-week high ($60.50), which the company reached on February 8th. The stock outperformed some of its competitors Monday, as Bank of America Corp. BAC, +1.39% rose 1.39% to $34.32, Great Southern Bancorp Inc. GSBC, +0.17% rose 0.17% to $58.49, and Wells Fargo & Co. WFC, +2.53% rose 2.53% to $45.03. Trading volume (8.1 M) remained 1.7 million below its 50-day average volume of 9.8 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_578

Signature Bank is putting even more distance between itself and digital assets—and its decision could ding the world’s largest cryptocurrency exchange, Binance. Signature Bank (ticker: SBNY), an FDIC-insured institution that was early to the crypto game, won’t support individual crypto customers who buy or sell amounts less than $100,000, Binance told Barron’s on Monday. “This is the case for all of their crypto exchange clients,” a Binance spokesperson said. The policy, which goes into effect in February, won’t allow customers to use the international banking network known as SWIFT—the Society for Worldwide Interbank Financial Telecommunication. Signature Bank was one of Binance’s U.S. SWIFT partners. Signature’s move affects 0.01% of Binance’s average monthly users and won’t affect the exchange’s functions, including the buying and selling of crypto with a credit card or other fiat currency such as the euro. “We are actively working to find an alternative solution,” the spokesperson said. Signature’s decision, reported over the weekend by Bloomberg News, shouldn’t come as a surprise. The bank stepped back from digital assets in December after a year of turbulence and was aiming to slash deposits linked to crypto. Limiting the use of SWIFT for customers trading crypto on Binance is a logical next step for a bank limiting its reputational and financial exposure to a volatile asset. Analysts had mixed reactions to Signature’s December step-back: the slashing of crypto deposits to less than 15% of total deposits. The analysts noted that walking away from some $10 billion would usher in funding pressures. Signature’s fourth-quarter earnings showed that digital asset-customer deposits in 2022 plunged by $12.4 billion, with total deposits at $88.6 billion. The bank’s stock price dropped almost 60% in the past year. Silvergate Capital (SI), another regulated way to play the crypto boom, suffered even more. Silvergate has seen its stock price collapse 85% in 12 months. So far, though, Signature and Silvergate have mostly just hurt themselves—and investors. Now Signature’s shift is proving to have wider consequences across crypto, and big banks fleeing digital assets are another reason to be skittish on Bitcoin. Write to Jack Denton at jack.denton@barrons.com

NEWS_579

The consumer electronics industry is getting new life from an old product: laptops. Although the changes are evolutionary rather than revolutionary, they’re substantial enough to make the laptop sector more competitive with the desktop PC sector of the market. This is especially significant as global PC sales tumbled 19.5% in the third quarter of 2022 — the largest decline since consulting firm Gartner began tracking sales in the mid-1990s. When you consider supply-chain issues, global economic crises and the crypto craze that took desktop graphic card prices sky-high last year, this is hardly surprising. In 2022, this lack of demand created a vacuum, and laptops are about to fill it. But these machines will need powerful CPUs and GPUs, and earlier this month at the Consumer Electronics Show (CES), consumers got a good look at what’s coming. Nvidia NVDA, +7.59% , AMD AMD, +9.22% and Intel INTC, +3.59% each showcased their own powerful mobile technology. Nvidia’s RTX 4000 mobile GPUs offer a more varied selection than the desktop versions. Intel’s Core i9-13980HX is the first 24-core laptop CPU that can be overclocked to 5.6GHz. Meanwhile, AMD’s Ryzen 7000 mobile processors focus on high-end performance while keeping low power consumption. Nvidia’s RTX 4000 mobile GPUs with DLSS 3 upscaling technology aim to make affordable and mid-range gaming laptops handle even the most graphically demanding games. Intel’s Core i9-13980HX also has the potential to narrow the performance gap between laptops and high-end desktop PCs. AMD’s Ryzen 7000 mobile processors with integrated RDNA 3 graphics could also create a generation of affordable laptops capable of running more PC games without a discrete GPU, which would help keep prices down and prolong battery life. While many of the laptops on display were simply updated versions of their predecessors, these stood out: Acer 2353, +1.45% Predator Helios 16 and 18 are excellent options for gamers looking for a balance of power and portability. Both models are equipped with Nvidia GeForce RTX 40-series GPUs, 13th-generation Intel i7 or i9 CPUs, and boast high-resolution screens with a maximum refresh rate of 240Hz. They also come equipped with ample storage and memory, which makes them ideal for running today’s latest and greatest games. Alienware m18 is a cutting-edge gaming laptop that is pushing the boundaries of possible in terms of screen size. It offers options of either 165Hz at 2560 x 1600 resolution or 480Hz at 1920 x 1200 resolution and includes the latest technology — Intel, Nvidia and/or AMD chips, up to 64GB of memory, and 9TB of storage. However, at $2,899 (starting for Intel CPU & Nvidia GPU), the price point is quite steep. Asus 2357, -0.37% ROG Zephyrus Duo 16 boasts a unique design with two screens — a traditional display and one above the keyboard. The laptop comes equipped with the latest AMD CPUs and Nvidia GPUs, a 240Hz QHD+ screen, and ample storage and memory. HP’s HPQ, +2.47% Omen 17 offers great flexibility with multiple configurations to choose from. The top-of-the-line version includes Nvidia GeForce RTX 40-series GPU, a 13th-gen Intel i9 CPU, 32GB RAM, 2TB SSD storage, and a high-resolution and refresh rate screen of 2560×1440 and 240Hz. Lenovo 992, +2.14% LNVGY, +1.44% Legion Pro 7i is a sleek and durable option with Nvidia GeForce RTX 40-series GPUs, 13th-gen Intel CPUs, and high-resolution and refresh rate screens. However, its configurations options are rather limited. The MSI Cyborg 15 is a powerful gaming model that features Intel Core i9-11900H processor, Nvidia GeForce RTX 3070 graphics, and a 1440p, 300Hz display. It also includes lightning-fast storage and memory, a mechanical keyboard, and Thunderbolt 4 connectivity. Unfortunately, while each of these models are impressive stats-wise, they offer little in regard to innovation. The same can be said for their business-use counterparts presented at the event, with a few notable exceptions: Lenovo Yoga Book 9i 2 in 1 with two 13.3-inch, Dolby Vision-powered screens is the first full-sized OLED dual-screen laptop. (The screens can be used in tandem, one on top of the other or side by side, depending on the user’s needs). Under the hood, the model boasts Intel 13th-gen Core i7-U15 processors and can support 16GB of LPDDR5X RAM and 512GB of storage. Priced at $2,100, it is expected in June of 2023. Lenovo ThinkBook Plus Twist features a rotating display that allows users to alternate between a clamshell or tablet position without compromising the display quality. The model comes with 13th-gen Intel Core processors, a 13.3-inch OLED display, a 12-inch E Ink display, noise-canceling microphones, and improved wireless connectivity. It is priced at $1,649 and will be available this June. Ultra-thin and lightweight, LG Gram Ultraslim weights about two pounds and is slightly thicker on one side to make room for ports. It boasts a 15.6-inch OLED display, a 13th-gen Intel Raptor Lake processor, and a customizable storage space of up to 512GB. Pricing is currently unavailable, but the model will be available overseas in February and in the U.S. later this year. Aside from showcasing aforementioned advancements in laptop technology, Advanced Micro Devices Inc. (AMD) and Nvidia Corp. used this year’s CES to vie for dominance in the market for AI acceleration chips. AMD CEO and Chair Lisa Su introduced the Instinct MI300 chip, a combined central processing and graphics processing unit meant for AI acceleration. The chip is billed as “world’s first data-center integrated CPU + GPU”, and Su claims it can reduce the time it takes for an inference modeling process to weeks from months. AMD doesn’t stop there; it introduced its Alveo V70 AI Accelerator, which boosts “energy efficiency for multiple AI inference workloads.” The company also announced it will release laptops with RX 7000-series graphics based on the AMD RDNA 3 architecture that offer “exceptional energy efficiency” and can run 30-plus hours of video on a single battery charge. From powerful mobile technology to larger screens for gaming laptops and AI acceleration chips, the industry clearly is commited to making laptops more capable, efficient, and cost-friendly for a broad range of users. With the emergence of larger and more powerful models, combined with AI acceleration chips, the laptop industry could be poised to make a major comeback and reclaim its stake in the PC market. More: AMD can keep eating Intel’s lunch, Barclays says as stock surges Plus: Big Tech layoffs are not as big as they appear at first glance

NEWS_580

Apple Inc. is expected to take on Meta Platforms Inc. with the launch of a mixed-reality headset later this year, but the company is likely to take a different approach than Meta to technology and pricing. Bloomberg News reported Monday that Apple AAPL, +2.35% could charge about $3,000 for the new headset upon its debut, a pricing level that would be double what Facebook parent Meta Platforms Inc. META, +2.80% charges for its Quest Pro device. Apple’s device, reportedly to be named Reality Pro, will function differently, according to Bloomberg. Whereas the Quest Pro headset has controllers that users click to execute tasks, Apple’s headset could have eye tracking and hand tracking. That would mean that users would be able to look at items within the headset and pinch their fingers together to choose one. Sensors would track their eyes, and cameras would track hand movements. Tech companies are still trying to determine which use cases will get users hooked on mixed-reality headsets, and in that sense, Apple’s approach might not depart too much from Meta’s at the outset. Bloomberg reported that videoconferencing and meeting rooms will be a key initial focus of the Apple device. Other likely features include immersive video and the ability for the device to serve as an external display for Macs. Users would be able to switch between virtual reality, which is immersive, and augmented reality, which layers virtual content over real-life surroundings, by using a dial similar to the one found on the Apple Watch. Apple has been developing the Reality Pro for more than seven years, according to Bloomberg News, and is looking for it to become a revenue driver at a time when overall growth is expected to slow. The FactSet consensus implies expectations for 2.1% revenue growth in fiscal 2023, compared with 7.8% growth in fiscal 2022. Apple didn’t immediately respond to a MarketWatch request for comment on the headset’s timing, pricing and technology.

NEWS_581

It will be a big week of fourth-quarter earnings, with about 90 S&P 500 companies scheduled to report. There will be plenty of notable economic data releases for investors to watch out for as well. Highlights will include results from Microsoft, Johnson & Johnson, General Electric, Verizon Communications, and Lockheed Martin —all on Tuesday. Wednesday will bring results from Tesla, AT&T, Boeing, and IBM. American Airlines Group, Comcast, Intel, Mastercard, Southwest Airlines, and Visa report on Thursday, then American Express, Charter Communications, and Chevron will close the week on Friday. On Monday, the Conference Board reports its Leading Economic Index for December, then S&P Global releases both the Manufacturing and Services Purchasing Managers’ Indexes for January on Tuesday. Both are expected to remain in contraction territory. On Thursday, the Bureau of Economic Analysis will report fourth-quarter gross-domestic-product, which is expected to show a 2.5% annual rate of growth. Also on Thursday, the Census Bureau will release the durable goods report for December. Read More Stock Futures Are Down Finally, the Bureau of Economic Analysis will report personal income and outlays for December on Friday. Earnings are expected to show a 0.2% month-over-month rise, while spending is seen slipping 0.1%. The Federal Reserve’s preferred inflation gauge will be part of the same report, and is forecast to be up 4.4% from a year earlier. Monday 1/23 Baker Hughes, Brown & Brown, and Synchrony Financia l report quarterly results. The Conference Board releases its Leading Economic Index for December. Consensus estimate is for a 0.6% month-over-month decline, after a 1% drop in November. Tuesday 1/24 Microsoft reports second-quarter fiscal-2023 results. The software giant recently announced 10,000 layoffs as part of cost-cutting measures. Analysts expect only 3% year-over-year revenue growth for the quarter, the slowest since 2016. 3M, Capital One Financial, Danaher, D.R. Horton, General Electric, Halliburton, Johnson & Johnson, Lockheed Martin, Paccar, Raytheon Technologies, Texas Instruments, Union Pacific, and Verizon Communications release earnings. S&P Global releases both its Manufacturing and Services Purchasing Managers’ Indexes for January. Economists forecast a 46.5 reading for the Manufacturing PMI and a 47.5 reading for the Services PMI. This compares with 46.2 and 44.7, respectively, in December. Wednesday 1/25 Abbott Laboratories, Ameriprise Financial, ASML Holding, AT&T, Automatic Data Processing, Boeing, Crown Castle, CSX, Elevance Health, Freeport-McMoRan, General Dynamics, Hess, IBM, Kimberly-Clark, Lam Research, Las Vegas Sands, Nasdaq, NextEra Energy, Norfolk Southern, ServiceNow, TE Connectivity, Tesla, and U.S. Bancorp announce quarterly results. Thursday 1/26 American Airlines Group, Archer-Daniels-Midland, Blackstone, Comcast, Dow, Intel, KLA, Marsh & McLennan, Mastercard, Northrop Grumman, Nucor, SAP, Sherwin-Williams, Southwest Airlines, Valero Energy, and Visa hold conference calls to discuss earnings. The Bureau of Economic Analysis reports fourth-quarter gross-domestic-product growth. The economy is expected to have grown at a 2.5% annual rate, following a 3.2% increase for the third quarter. The Census Bureau releases the durable goods report for December. The consensus call is for new orders for manufactured durable goods to increase 2.5%, to $277 billion. Friday 1/27 American Express, Charter Communications, Chevron, Colgate-Palmolive, HCA Healthcare, and Roper Technologies report quarterly results. The BEA reports personal income and outlays for December. Personal income is expected to rise 0.2% month over month compared with a 0.4% gain in November, while spending is seen declining 0.1% after rising 0.1% previously. The Federal Reserve’s favored inflation gauge, the core personal-consumption expenditures price index, is forecast to increase 4.4% year over year, three-tenths of a percentage point less than in November. Write to Nicholas Jasinski at nicholas.jasinski@barrons.com

NEWS_582

Shares of Visa Inc. Cl A V, -0.06% shed 0.06% to $224.18 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. The stock's fall snapped a two-day winning streak. Visa Inc. Cl A closed $11.67 short of its 52-week high ($235.85), which the company reached on February 2nd. The stock underperformed when compared to some of its competitors Monday, as JPMorgan Chase & Co. JPM, +1.62% rose 1.62% to $137.27, Bank of America Corp. BAC, +1.39% rose 1.39% to $34.32, and Mastercard Inc. MA, +0.61% rose 0.61% to $378.57. Trading volume (5.5 M) remained 1.2 million below its 50-day average volume of 6.7 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_583

To get a sense of who is truly in control of V.F. Corporation (NYSE:VFC), it is important to understand the ownership structure of the business. With 90% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). And institutional investors endured the highest losses after the company's share price fell by 5.8% last week. Needless to say, the recent loss which further adds to the one-year loss to shareholders of 55% might not go down well especially with this category of shareholders. Also referred to as "smart money", institutions have a lot of sway over how a stock's price moves. As a result, if the downtrend continues, institutions may face pressures to sell V.F, which might have negative implications on individual investors. Let's take a closer look to see what the different types of shareholders can tell us about V.F. View our latest analysis for V.F What Does The Institutional Ownership Tell Us About V.F? Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. V.F already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at V.F's earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. V.F is not owned by hedge funds. The Vanguard Group, Inc. is currently the largest shareholder, with 11% of shares outstanding. PNC Financial Services Group Inc., Banking Investments is the second largest shareholder owning 10.0% of common stock, and Capital Research and Management Company holds about 8.6% of the company stock. Story continues We also observed that the top 7 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. Insider Ownership Of V.F The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of V.F. Corporation in their own names. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own US$41m of stock. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling. General Public Ownership With a 10% ownership, the general public, mostly comprising of individual investors, have some degree of sway over V.F. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. Next Steps: I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that V.F is showing 4 warning signs in our investment analysis , and 2 of those can't be ignored... Ultimately the future is most important. You can access this free report on analyst forecasts for the company. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Join A Paid User Research Session You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

NEWS_584

Shares of VF Corp. VFC, +3.92% advanced 3.92% to $30.49 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. VF Corp. closed $38.99 short of its 52-week high ($69.48), which the company reached on January 27th. The stock outperformed some of its competitors Monday, as Nike Inc. Cl B NKE, +1.32% rose 1.32% to $128.29. Trading volume (4.1 M) remained 2.3 million below its 50-day average volume of 6.4 M.

NEWS_585

Par Petroleum (PARR) shares rallied 8.4% in the last trading session to close at $26.61. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.5% gain over the past four weeks. Par Pacific stock extended its rally for the seventh straight day, driven by optimism over oil prices spurred by the potential demand boost from the easing of coronavirus restrictions in China. The recent strength in crude prices (at above $80 a barrel) and robust demand for energy has lifted the fuel refining space and contributed to the share price movement in Par Pacific. Besides, an improving macro environment prompted Piper Sandler analyst Ryan Todd to upgrade the rating on Par Pacific to Outperform from Neutral with a higher price target. This independent oil and gas company is expected to post quarterly earnings of $1.46 per share in its upcoming report, which represents a year-over-year change of +763.6%. Revenues are expected to be $1.9 billion, up 46.7% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Par Petroleum, the consensus EPS estimate for the quarter has been revised 5.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on PARR going forward to see if this recent jump can turn into more strength down the road. The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Par Petroleum is a member of the Zacks Oil and Gas - Refining and Marketing industry. One other stock in the same industry, Valero Energy (VLO), finished the last trading session 3.1% higher at $142.73. VLO has returned 15.8% over the past month. Story continues Valero Energy's consensus EPS estimate for the upcoming report has changed +1.9% over the past month to $7.25. Compared to the company's year-ago EPS, this represents a change of +193.5%. Valero Energy currently boasts a Zacks Rank of #3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Par Pacific Holdings, Inc. (PARR) : Free Stock Analysis Report Valero Energy Corporation (VLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NEWS_586

Shares of Valero Energy Corp. VLO, +0.25% inched 0.25% higher to $143.08 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's third consecutive day of gains. Valero Energy Corp. closed $3.73 below its 52-week high ($146.81), which the company achieved on June 8th. The stock outperformed some of its competitors Monday, as Exxon Mobil Corp. XOM, -0.52% fell 0.52% to $112.76 and Chevron Corp. CVX, -0.13% fell 0.13% to $180.66. Trading volume (3.9 M) remained 11,295 below its 50-day average volume of 3.9 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_587

Shares of Vulcan Materials Co. VMC, +0.31% inched 0.31% higher to $179.45 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Vulcan Materials Co. closed $13.86 below its 52-week high ($193.31), which the company reached on February 10th. Trading volume (719,929) eclipsed its 50-day average volume of 619,229. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_588

Shares of Vornado Realty Trust VNO, +0.76% inched 0.76% higher to $22.42 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Vornado Realty Trust closed $24.84 below its 52-week high ($47.26), which the company achieved on March 11th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as JBG SMITH Properties JBGS, +1.96% rose 1.96% to $19.29, Broadstone Net Lease Inc. BNL, remained unchanged, and Essential Properties Realty Trust Inc. EPRT, +1.24% rose 1.24% to $24.40. Trading volume (2.3 M) remained 2.4 million below its 50-day average volume of 4.8 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_589

Shares of Verisk Analytics Inc. VRSK, +2.06% advanced 2.06% to $185.36 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Verisk Analytics Inc. closed $36.75 short of its 52-week high ($222.11), which the company achieved on April 6th. The stock outperformed some of its competitors Monday, as Fair Isaac Corp. FICO, +0.12% rose 0.12% to $649.95 and Prism Technologies Group Inc. PRZM, remained unchanged. Trading volume (832,621) remained 62,567 below its 50-day average volume of 895,188. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_590

Shares of VeriSign Inc. VRSN, +0.28% inched 0.28% higher to $215.51 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. VeriSign Inc. closed $13.29 below its 52-week high ($228.80), which the company reached on April 4th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Equinix Inc. EQIX, -0.52% fell 0.52% to $716.32, Zscaler Inc. ZS, +5.67% rose 5.67% to $123.76, and Arista Networks Inc. ANET, +3.50% rose 3.50% to $119.16. Trading volume (748,527) eclipsed its 50-day average volume of 738,292. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_591

Shares of Vertex Pharmaceuticals Inc. VRTX, +0.64% inched 0.64% higher to $311.81 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Vertex Pharmaceuticals Inc. closed $12.94 short of its 52-week high ($324.75), which the company reached on December 8th. The stock outperformed some of its competitors Monday, as AbbVie Inc. ABBV, -0.70% fell 0.70% to $148.55, Krystal Biotech Inc. KRYS, -1.79% fell 1.79% to $79.78, and Arcturus Therapeutics Holdings Inc. ARCT, +0.32% rose 0.32% to $18.88. Trading volume (1.8 M) eclipsed its 50-day average volume of 1.4 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_592

Shares of Ventas Inc. VTR, +2.86% rallied 2.86% to $50.69 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of gains. Ventas Inc. closed $13.33 short of its 52-week high ($64.02), which the company reached on March 29th. The stock outperformed some of its competitors Monday, as Welltower Inc. WELL, +1.99% rose 1.99% to $74.28, Boston Properties Inc. BXP, -0.04% fell 0.04% to $71.17, and Healthpeak Properties Inc. PEAK, +1.71% rose 1.71% to $27.31. Trading volume (1.7 M) remained 476,194 below its 50-day average volume of 2.2 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_593

PITTSBURGH, PA / ACCESSWIRE / January 23, 2023 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, announced it is donating a total of $1 million to aid in supporting access to healthcare, food security and water stewardship in communities around the world, through four organizations: Direct Relief, World Central Kitchen (WCK), WaterAid and World Food Program USA, the U.S. partner of the United Nations World Food Programme. "As a signatory to the UN Global Compact and supporter of the UN Sustainable Development Goals, we believe companies can play an important role in helping to enable potential solutions to some of society's most pressing challenges," said Michael Goettler, CEO of Viatris. "Guided by our mission to empower people worldwide to live healthier at every stage of life, we are committed to advancing sustainable access to treatment as well as addressing factors impacting the health and well-being of people and communities." The world continues to face many challenges, including the continuing impacts of the COVID-19 pandemic, growing disparities in access to healthcare, increasing effects of climate change, water crisis and conflicts. According to the World Health Organization, globally more than 770 million people lack access to safe water while as many as 828 million people are at risk of hunger. Partnerships are essential for meaningful impact and in that spirit, Viatris is proud to support organizations committed to causes that enable people to access fundamental human needs, manage determinants of health and improve their quality of life. The company has contributed $250,000 donations to each of the following organizations to support people and communities with emerging needs that directly tie to overall human health and that support Viatris' mission: Direct Relief works globally to expand access to medicine and healthcare by equipping doctors and nurses with lifesaving medical resources. They respond to crises of all types, including the war in Ukraine, hurricanes in the U.S., flooding in Pakistan and COVID-19. World Central Kitchen (WCK) is the first to the frontlines, providing meals in response to humanitarian, climate, and community crises while working to build resilient food systems with locally led solutions. WCK has served more than 200 million fresh meals to people impacted by natural disasters and other crises around the world. WaterAid works with communities to deliver clean water, sanitation and hygiene with a belief that these three essentials are the foundation of good health and quality healthcare. With presence in more than 30 countries from Latin America to South Asia, the organization works to build resilient water systems so that clean water, decent toilets and good hygiene are accessible for everyone, everywhere. World Food Program USA supports the mission of the United Nations World Food Programme (WFP) by mobilizing American policymakers, businesses and individuals to advance the global movement to end hunger. They save lives in emergencies and use food assistance to build a pathway to peace, stability and prosperity for people recovering from conflict, disasters, and the impact of climate change. Story continues To learn more about Viatris' sustainability efforts and how the company is partnering with stakeholders globally to address some of the world's most pressing health, environmental and social issues, please read the company's 2021 Sustainability Report, which outlines Viatris' 2021 progress, achievements and commitments across key areas including access and global health, employees, environmental stewardship and community engagement. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube. For further information: Contacts: MEDIA,+1.724.514.1968, Communications@viatris.com; Jennifer Mauer, Jennifer.Mauer@viatris.com; Matt Klein, Matthew.Klein@viatris.com; INVESTORS, +1.412.707.2866, InvestorRelations@viatris.com, Bill Szablewski, William.Szablewski@viatris.com Viatris, Monday, January 23, 2023, Press release picture View additional multimedia and more ESG storytelling from Viatris on 3blmedia.com. Contact Info: Spokesperson: Viatris Website: https://www.3blmedia.com/profiles/viatris Email: info@3blmedia.com SOURCE: Viatris View source version on accesswire.com: https://www.accesswire.com/736399/Viatris-Announces-Donations-Totaling-1-Million-To-Provide-Aid-Supporting-Access-to-Healthcare-Food-Security-and-Water-Stewardship

NEWS_594

Shares of Verizon Communications Inc. VZ, -0.93% dropped 0.93% to $39.63 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.19% rising 1.19% to 4,019.81 and the Dow Jones Industrial Average DJIA, +0.76% rising 0.76% to 33,629.56. This was the stock's second consecutive day of losses. Verizon Communications Inc. closed $15.88 short of its 52-week high ($55.51), which the company reached on April 21st. The stock underperformed when compared to some of its competitors Monday, as Apple Inc. AAPL, +2.35% rose 2.35% to $141.11, AT&T Inc. T, -0.68% fell 0.68% to $19.10, and T-Mobile US Inc. TMUS, -0.52% fell 0.52% to $144.37. Trading volume (34.2 M) eclipsed its 50-day average volume of 24.0 M. Editor's Note: This story was auto-generated by Automated Insights, an automation technology provider, using data from Dow Jones and FactSet. See our market data terms of use.

NEWS_595

Verizon Communications Inc. already disclosed that it reversed its negative subscriber trends in the fourth quarter, but there’s more to be shared about the company’s story. The wireless giant is set to post fourth-quarter results Tuesday morning amid continued skepticism on Wall Street about the company’s ability to drive a bigger change in its business. Verizon VZ, -0.93% may have stemmed the bleeding after three quarters in a row of subscriber declines in its consumer postpaid business, but analysts, who are mainly neutral-rated on the stock, have questions about Verizon’s ability to pick up real momentum in a competitive wireless market. See more: What’s ahead for Verizon? After a dismal 2022, it’s time to hear the turnaround plan. Here’s what to expect ahead of Verizon’s report, which is due out before Tuesday’s opening bell. What to expect Earnings: Analysts tracked by FactSet expect the company to post adjusted earnings per share of $1.19 for the fourth quarter, down from $1.31 a year before. According to Estimize, which crowdsources projections from hedge funds, academics and others, the average estimate calls for $1.22 a share. Revenue: Analysts surveyed by FactSet anticipate that Verizon generated $35.09 billion in revenue for the latest quarter, up from $34.10 billion a year before. Those contributing to Estimize expect $35.16 billion on average. Stock movement: Verizon shares have fallen following each of the company’s past four earnings reports. The stock is up 12% over the past three months, though it’s fallen 25% over a 12-month span. Of the 28 analysts tracked by FactSet who cover Verizon’s stock, seven have buy ratings, 19 have hold ratings, and two have sell ratings, with an average price target of $44.34. What to watch for While Verizon Chief Executive Hans Vestberg already teased that the company achieved its goal of positive consumer subscriber growth in the fourth quarter, but the company has yet to reveal the scale of those gains. Evercore ISI analysts led by Vijay Jayant expect that the company saw 50,000 postpaid phone net additions in its consumer business, down from the 336,000 it saw in the fourth quarter of 2021. They anticipate that Verizon saw a 12-basis-point increase in its churn relative to a year ago. Don’t miss: Looking for clues about iPhone supply? Ask AT&T, Verizon and T-Mobile The company’s outlook for fiscal 2023 will also be of key interest. “We are expecting Verizon’s 2023 guidance to be impacted by the same competitive and macro pressures that led to management lowering 2022 guidance in July — cost inflation, competition, increased promotional subsidies, higher interest rates, and business vs. consumer customer growth mix,” wrote Deutsche Bank analyst Bryan Kraft. In addition, he notes the potential for “a slower demand ramp in 5G mobile edge compute services and higher cash taxes (possibly, depending on management’s assumptions underlying the FCF [free-cash-flow] guidance).” However, such pressures “appear to already be reflected in consensus estimates,” Kraft added. See also: AT&T could ‘turn the corner’ on a key metric this year Verizon’s narrative continues to invite skepticism on Wall Street. “We find the near-term setup to be negative for VZ with the valuation above historical averages and fundamentals struggling to show sustainable growth,” wrote KeyBanc Capital Markets analyst Brandon Nispel, who has a sector-weight rating on the stock. “We are below consensus estimates and see headwinds to EPS [earnings-per-share] growth that are likely to cause a short-term negative reaction to the stock.”

NEWS_596

Verizon Sourcing LLC NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Verizon Communications Inc. (NYSE, Nasdaq: VZ) will report fourth-quarter 2022 earnings on Tuesday, January 24. The company will present results on a webcast beginning at 8:30 a.m. Eastern Time. Access instructions and presentation materials will be available at 7:00 a.m. on Verizon’s Investor Relations website, https://www.verizon.com/about/investors . These materials include: Detailed commentary on Verizon’s fourth quarter and full year results; Verizon’s earnings news release; and Financial tables. Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is one of the world’s leading providers of technology and communications services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $133.6 billion in 2021. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control. VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at verizon.com/news. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/. Media contact: Eric Wilkens eric.wilkens@verizon.com 201-572-9317 @ericwilkens

NEWS_597

Verizon Sourcing LLC New Home Internet customers can take advantage of free delivery from a Walmart store, a Paramount+ subscription, fuel discounts and more What’s the news? Starting January 26, switch to Verizon Home Internet and get up to 12 months of Walmart+ on us1 – Walmart’s membership program that can help members save over $1,300 each year. Who’s it for? New customers looking to switch to Verizon Home Internet2 – all on the network America relies on. Why is it important? For the first time, Verizon is teaming with Walmart for an exclusive offer that brings even more value to customers on our Home Internet plans, with perks like free delivery from Walmart stores, member savings on fuel, access to Paramount+ and more. NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Verizon is giving you even more reason to ditch cable and switch to Verizon Home Internet. Starting January 26, customers who switch to Verizon Home Internet can get up to 12 months of Walmart+ on us (then $12.95/mo. thereafter) – a $155 annual value! Walmart+ is a membership service that can help customers save over $1,300 each year, bringing together in-store and online benefits to save customers money and time. Benefits include3: Free delivery from Walmart: Get fresh groceries and more with $0 delivery fees, all at the same low in-store prices (that means no item markups!). Free shipping at Walmart with no minimum order: Even small orders ship for free! Choose from a huge assortment of eligible items and never pay shipping fees. Fuel discounts : Save up to 10 cents per gallon on gas at 14,000+ locations nationwide including Exxon, Mobil, Walmart & Murphy stations. Paramount+ Essential : Enjoy over 40,000 episodes, hit movies, live sports and more with a Paramount+ subscription at no extra cost. Walmart Rewards for members: Earn rewards on eligible items online & in-store to use on future Walmart purchases. Exclusive early access: Members enjoy special prices, product releases, online Black Friday deals & more. Mobile ‘Scan & Go’ in-store: Use your phone to scan items as you shop in-store & check out contact-free. Fast. Easy. Done! Access to other limited time offers. Story continues “Verizon Home Internet is already an incredible value - but we wanted to give our customers even more, so we teamed up with Walmart to offer customers access to savings on critical household expenses like fuel and groceries, plus all of the other amazing benefits that Walmart+ offers,” said John Granby, Senior Vice President of Home Readiness and Orchestration for Verizon. Pair your mobile service with Verizon Home Internet Our award-winning Fios Home Internet, our 5G Home Internet and LTE Home Internet on the network America relies on are all available to customers starting at the low price of $25 per month with AutoPay and an existing premium 5G mobile plan4 – with no extra fees, equipment charges, annual contracts or data caps. Plus, to make your dollar go even further, you can join Verizon on our Welcome Unlimited plan – with unlimited talk, text, and data on Verizon’s 5G Nationwide network – for just $25 per line per month for four lines when you bring four phones5. And the price is guaranteed for three years! No need to buy a new phone. Just bring the one you have, it’s that easy. To learn more about Verizon Home Internet services, visit your local Verizon retail store, or head to verizon.com/home and plug in your address to see what service is available in your area. 1. Walmart+: Offer valid thru 4.12.23. Must install eligible Fios or 5G Home Plus services and redeem offer through Walmart w/in 60 days of installation or activation date, or by no later than 7.12.23, whichever is first. After the 3, 6 or 12-month promo period ends, your membership will auto-renew at $12.95/mo or the then current monthly rate, unless you cancel. Cancel anytime. If you are a current annual Walmart+ member through Walmart and use the same email for both your Walmart+ and Verizon accounts, your Walmart+ promo through Verizon will be applied when your current Walmart+ billing cycle ends. One offer per eligible Verizon account. Subject to Walmart+ Terms of Use found at walmart.com/plus. 5G Home Plus: 5G Home available in select areas. 2. Customers selecting a 5G Home or LTE Home plan must be internet-only (non-mobile) customers new to Verizon. New internet customers selecting a Fios or 5G Home Plus plan may be new or existing Verizon mobile customers. Depending on plan selected, customers will receive a 3, 6, or 12 month Walmart+ subscription on us. 3. Subject to additional terms and conditions. See walmart.com/plus for more. 4. Verizon Home Internet includes 5G Home, LTE Home and Fios internet services. Availability varies. New 5G Home, LTE Home, and Fios 300 Mbps plans start at $25/mo. when combined with an existing 5G Do More, 5G Play More, 5G Get More or One Unlimited for iPhone plan. Fios requires Mobile + Home Discount enrollment; $99 Fios setup charge may apply. Auto Pay and paper-free billing req'd. $10/mo. more w/o Auto Pay. Subject to credit approval. 5. BYOD: $180 promo credit per phone applied over 36 mos when you add 4 new smartphone lines with your own 4G/5G smartphone on Welcome Unlimited plan. Limited time offer. Promo credit ends if eligibility req’s are no longer met. 3-year price guarantee: Applies only to then current base monthly rate; excludes taxes/fees, add’l plan discounts or promotions, and third-party services. Price guarantee void if any of the 4 lines are upgraded, canceled or moved to an ineligible plan. Welcome Unlimited: $30/line for 4 lines, less $5/line discount. Auto Pay & paper-free billing req’d. Unlimited 5G Nationwide/4G LTE: In times of congestion, your data may be temporarily slower than other traffic. All smartphone lines on the account must be on Welcome Unlimited and are eligible only for select device/other promotions. Domestic data roaming at 2G speeds. Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is one of the world’s leading providers of technology and communications services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $133.6 billion in 2021. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control. VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at verizon.com/news. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/. Media contact: Caroline Brooks caroline.brooks@verizon.com Andrew Testa andrew.testa@verizon.com

NEWS_598

Stocks posted solid gains Monday on optimism about the economic outlook and as traders prepared for a busy week of earnings reports. These stocks were making moves Monday: Wayfair (ticker: W) shares gained 27% after surging more than 20% on Friday when the home furnishings retailer announced it was cutting about 1,750 employees, or 10% of its workforce. On Monday, the stock was upgraded to Overweight from Underweight at J.P. Morgan, and was upgraded to Buy from Underperform at BofA. Xylem (XYL) shares dropped 8% after the water technology company said it would acquire Evoqua (AQUA), a wastewater treatment systems company, in an all-stock transaction with an implied enterprise value of about $7.5 billion. Shares of Evoqua were up 15% to $47.28. Western Digital (WDC) gained 8.7% after Bloomberg reported that the company’s merger talks with fellow data-storage company Kioxia Holdings were progressing. Advanced Micro Devices (AMD) rose 9.2% and Qualcomm (QCOM) gained 6.6% after shares of the chip makers were upgraded to Overweight from Equal Weight at Barclays. The analysts raised their price target on Nvidia (NVDA) to $250 from $170 and maintained their Overweight rating. Nvidia closed 7.6% higher. Shopify (SHOP) rose 8.8% Monday after stock of the e-commerce software company was upgraded to Buy from Hold by analysts at Deutsche Bank. Newell Brands (NWL) jumped 6.1% after the maker of Rubbermaid, Sharpie pens and Expo markers announced Monday it planned to cut about 13% of office positions. Caesars Entertainment (CZR) rose 5.9% after the casino company disclosed in a regulatory filing fourth-quarter revenue estimates that surpassed analysts’ expectations. Skechers (SKX) rose 4.6% after Cowen analysts raised their rating on the stock to Outperform from Market Perform. The footwear company is gaining popularity as consumers appear less willing to spend on discretionary goods, analysts wrote. Synchrony Financial (SYF) fell 2.4% after it reported fourth-quarter earnings of $577 million, down from $813 million a year earlier. The bank’s provision for credit losses in the quarter was $1.2 billion, up from $561 million. Write to Joe Woelfel at joseph.woelfel@barrons.com and Emily Dattilo at emily.dattilo@dowjones.com

NEWS_599

Shares of Wayfair soared after a JP Morgan analyst double-upgraded the stock to Overweight and raised its price target by 80%. Video Transcript DAVE BRIGGS: My play is Wayfair, a trending ticker on Yahoo Finance. Shares soaring again today as JP Morgan's Christopher Horvers doubled upgraded the stock to overweight and increased his price target by 80% to $63 from $35. Horvers' upgrade based on, quote, "a positive shift in market-share trends and management's newfound commitment to controlling expenses." Now on Friday, the stock popped more than 20% after the company announced it was cutting about 10% of its workforce as part of a broader cost-cutting plan. If it holds, this would be the stock's biggest two-day rally since April 2020. As you can see, shares up 25 plus percent on this day and up more than 80% year to date. Still, though, down more than 60% over the last year. But boy, they represent one of the biggest rallies we've seen this year. Just a rocket ship. SEANA SMITH: They have, and rally off of an extremely depressed level when you take into account the losses that you were just talking about over the last year, over the past two years. I think the big question going forward with Wayfair is the amount of cost cuts that still may be possibly on the table. This is a step in the right direction. The cost cuts that they announced-- job cuts that they announced last week was about 1,200 corporate jobs. So they're working to eliminate some of those management layers that they talked about, really restructure their business in order to be more agile in this environment. The Street is getting more positive. JP Morgan isn't alone. Wells Fargo was positive on the cuts last week. Truist saying that it makes sense. But I think in this environment, they're still going to potentially struggle a little bit given the state of the consumer and what that could maybe look like in the next quarter. DAVE BRIGGS: You hear nothing about demand in those upgrades. It would be nice to hear that if you're a true believer. SEANA SMITH: Yeah, I think that's-- yeah, that is a key word that would be nice to--